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Aim and Scope of this Dissertation 
The polysaccharides that extracted from many Chinese herbs such as Pseudostellaria 
heterophyUa, Astragalus rm-mhranoceus y Angelica radix, etc. were found to have 
immunostimulating and anti-tumour activities (Han et oL, 1991). 
Another report stated that Bupleuri radix have anti-tumour activities (Haranaka et 
oL, 1985). However, the anti-tumour activities mentioned was einphasizecl on TNF 
production only. Also, the above anti-tumour activities was studied using BR crude 
extract only. Since the mechanism by which the anti'tumour activities of Chinese 
traditional herbs was seldom reported, in order to understand more about the 
mechanism of anti'tumour and immunostimulating activities, it is of interest to 
isolated bioactive components from Bupleuri radix in pure form. The studies of the 
effect of these pure components on the anti'tumour activities and 
immunostimulating activities on animal system are carried out using cell cultures 
as well as animal models. However, the aim of this study is to explore the 
underlying effects of Bupleuri radix, so that it can be used in clinical trial for cancer 
treatment in the future. 
Abstract X 
Abstract 
Hot water extract of Bupleuri radix (BR), a Chinese traditional herb was separated 
into fractions (zero, I, II, III and IV) by stepwise alcohol precipitation. Each of 
these fractions is a heteropolymer consisting mainly carbohydrate and varying 
proportions of protein. The carbohydrate content of certain fractions contains large 
proportion of uronic acid. 
BRI was found to exhibit the most potent mitogenic activity on murine 
lymphocytes both in vitro and in vivo, and powerful anti-tumour activities against 
Ehrlich ascites tumour (EAT) cells in EAT-bearing mice. BRI was then 
fractionated into BRIa and BRIb by gel chromatography using G-lOO sephadex, 
and the above fractions obtained were further purified into BRIai, BRIaii, BRIbi 
and BRIbii by ion exchange chromatography using DEAE-sephadex. The BR 
fractions separated were not cytotoxic to brine shrimps and splenocytes cultured 
in vitro. 
BRIbii was found to exhibit the most potent mitogenic activity on murine 
lymphocytes in vitro. It was also a good immunopotentiator on macrophages, by 
AL)stract XI 
enhancing the in vivo migration of macrophages and the expression of Fc receptor 
on the cell surface. Moreover, it was able to induce the production of various 
cytokines, like I H , IL'2 and GM-CSF, and the expression of IL'2R on murine 
lymphocytes. It could also restore lymphocyte blastogenesis in aged mice and 
tumour^bearing mice. 
On the other hand, BRIaii書 in spite of weak in vitro cytostatic effect on murine cell 
lines, was found to show strong anti-tumour activities in various aspects. These 
include (i) EAT, MBL'2 and WEHI-164 cells suppression in vivo； (ii) enhancement 
of macrophage-mediated cytostasis and cytolysis on L929 and WEHI464 cells; (iii) 
induction of NK cells and LAK cells activation; (iv) induction of increase in TIL 
number and (v) induction in IFN-y production. 
Cfiapter One 
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L I A N OVERVIEW OF THE IMMUNE SYSTEM 
LLl Innate Immunity 
Innate or natural immunity includes all nonspecific resistance or immune 
mechanism, which does not require learning. It divides into the items of cellular 
part and soluble factors: 
Granular leukocytes include neutrophils, eosinophils and basophils. The number 
of neutrophils increases during infections, since they provide the first line of 
defense against invading foreign materials and microorganisms. In allergies and 
parasitic diseases, the number of eosinophils increases. Basophils are important for 
the production of histamine, the primary cause of skin reactions in allergic 
responses. 
Macrophages and Monocytes, present in several organ systems, not only participate 
in cell'mediated immune reactions, but also handle or process antigen, and they 
therefore play an indirect role in antibody synthesis. The leukocytes that possess 
the most actively phagocytic power are neutrophils and macrophages. These cells 
� 
ingest foreign particles, bacteria, immune complexes and degenerating cells and 
fragments in a nonspecific manner. Phagocytosis can contribute significantly to an 
animars resistance to infectious organisms. When the macrophage engulfs antigen, 
it is then ready to be processed, performing a series of events that lead to a specific 
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immune response (Cooper, 1981). 
Natural killer cells are another kind of phagocytic cells like macrophages, which, 
together with the macrophages, probably constitute the most primitive evolutionary 
form of innate immunity. NK cells lineage may have evolved and developed 
independently of T cells, B cells and monocytes into a separate group of cells 
capable of antibacterial, anti-protozoan, anti-viral, and anti-tumour activities 
(Evans, et d” 1990). 
Interferons protect host cells against virus infection. Macrophages are an 
important source of interferon, especially in the lungs. 
Humoral factors include the complement proteins, acute phase proteins and 
molecules such as isozyme and spermine. As a component of innate immunity, 
complement can be activated in the absence of antibody, but like the phagocytic 
system, its utility is greatly enhanced by antibody coating the foreign material. 
L1.2 Adaptive Immunity 
The Adaptive Immunity is defined as the immunity to a particular pathogen 
developed after initial exposure to the antigen. After a primary immune response 
to a pathogen’ an acquired immunity will be developed, so that any further 
infection by that pathogen is immediately processed by the body. The secondary 
Ch. One General Introduction 4 
or acquired immune response to the pathogen is more rapid and of greater 
magnitude and thus provides stronger protection against infection. 
The adaptive immunity is characterized by its specificity to foreign materials and 
the bearing of memory cells. 
1.1.2.1 Humoral antibody immune response - During primary infection, the 
antigen is usually handled at the site of entry and in nearby lymph 
nodes by various phagocytic cells such as macrophages. These cells 
process the antigen and present pathogen derived peptides to CD4 
and CD8十 T cells in association with the Major Histocompatibility 
Complex (MHC), Antigen binding by surface immunoglobulin, and 
"help" by CD4十 T cells, induce B cells to differentiate to plasma cells, 
secreting a specific antibody to bind with the antigen. During a 
primary immune response, there is a time lag of approximately 3-4 
days before antigen specific antibody is evident in serum, and the 
levels does not reach maximum until approximately Day 7. The class 
of antibody produced is primarily IgM. However, if the same antigen 
is encountered by the immune system anytime after the primary 
response, increased levels of IgG antibodies appear in the serum 
within 24 hours of infection. It is because many B cells differentiate 
to memory B cells during the primary response. These memory B cells 
� 
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have been found to be long-lived and are able to produce a strong and 
rapid humoral immune response (Leanderson, et al, 1987). 
1.1.2.2 Cell-mediated immune response - Cell-tiiediated immunity refers to 
those types of immune responses initiated by T lymphocytes and 
mediated by T lymphocytes and macrophages, while humoral 
immunity is mediated by antibodies. CD4十 T cells react with 
processed fragments of antigens which are associated with MHC class 
II molecules and presented by antigen presenting cells (Lanzavecchia, 
1989). CDS十 T cells, which are also called cytotoxic T lymphocytes 
(CTL) can directly lyse target cells that express the appropriate 
antigens in association with MHC class I molecules. These target 
cells, which are considered by the immune system to be ^non-self, 
include those viral transformed cells and tumour cells. Moreover, T 
cells can carry out many effector functions through the secretion of 
cytokines which further modulate the activities of various cells in the 
immune system. 
Like humoral immune response, antigen specific T cells are clonally 
expanded during the primary inimune response, some of them 
differentiate to memory T cells. It is believed that this expansion 
provides a further level of protection from reinfection. However, it is 
> .. 
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Still unclear why these cells are long-lived (Cerottini, 1990). 
1,2 IMMUNOMODULATION 
Imniunomodulation can be defined as the modulation of the immune system by 
certain agents, known as immunomodulators which can promote or depress the 
ability of an animal to trigger an immune response against pathogens or tumours. 
In this thesis, the research is focused on the immunomodulation in which the 
immune response is up^regulated, which is also known as immunopotentiation. 
Nowadays, an enormous number of crude biological extracts, plant, animal and 
bacteria substances of varying degrees of purity, cloned cytokines and highly 
purified immunoglobulins have been used as immunopotentiating agents. 
It is possible to classify immunopotentiation in a number of ways, as shown in 
Table 1. 
A summary of the different categories of iinmunomociulators of biological origin 
that have been used is shown in Table 2. In general, these agents have been used 
both as adjuvants in vaccination procedures and as immunotherapeutic tools for 
neoplasms and to a lesser extent infectious disease. The specific mechanisms by 
which these compounds exert their effect on various cellular compounds of the 
immune system are very unclear. It is not known whether the agents act directly 
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Table LI Classification of immunopotentiation (Gatenby, 1992) 
Specific mechanisms 
Active: Vaccination 
Passive: Xenogeneic antibody therapy 
Hyperimmune globulin 
Adoptive: Sensitized lymphocytes - allogeneic, xenogeneic, or autologous. 
Tumour infiltrating lymphocytes (TIL) 




Active： Iminunopotentiators of biological origin 
Thymosins and other hormone-like thymic extracts 
Cytokines 
Synthetic chemicals 
Passive: Immunoglobulin therapy 
Plasmapheresis 
Adoptive: Cytokine'activated killer cells 
� 
Ch» One General Introduction 8 
Table 1*2 Immunopotentiators of biologic origin (Gatenby, 1992) 
Bacterial preparations 
Bacillus Calmette-Guerin (BCG) 
Corynebacterium parvum (C.parvum) 
Bardetella pertussis 
Extracts of microorganisms 
Methanol extractable residue (MER) of BCG 
Chemically identified bacterial extracts 
Muramyl dipeptide (M. sme^atis, BCG) 
Peptidoglycans 
Lipopolysaccharide (LPS) 




‘ , \ 
/ 
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by combining with cellular receptors and activating the cells to effectors, or, 
alternatively, whether intermediate steps are involved whereby the cells stimulated 
by the agents release soluble mediators that in turn activate effector cells (Fauci, 
ET OL, 1987). 
It is possible that the cellular effects induced by many of the immunopotentiators 
may be through their capacity to elicit the production and secretion of cytokines 
(e.g. IL'l, TNF, IFN'y, IL'2, etc.), which are regarded as the direct cellular 
regulatory factors. The differences between the various stimulatory biological 
products may depend upon minor variations in production of the different 
cytokines. 
These substances have primarily been used as immunotherapy for a wide variety 
of neoplasms in animals and man. Such therapy has been combined with�alleged 
tumour antigens* or made part of a multimodality approach to cancer including 
surgery, chemotherapy, and radiotherapy (Hadden’ et d” 1985). 
1 3 A N OVERVIEW OF THE HOST-MEDIATED RESPONSE AGAINST 
TUMOURS 
1.3.1 T FLTUF B 
T lymphocytes can be divided into three main subsets: Helper T cells 
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(CD4十),Cytotoxic T cells (CDS十)and Suppressor T cells (CDS十)• 
Regarding tumour immunology, there is no report telling that suppressor T 
cells take part in the host-mediated response against tumours. Therefore, 
only helper T cells and cytotoxic T cells will be mentioned. 
The T cell response against virus induced tumours is almost the same as the 
T cell immunity against viruses in general. Thus, both CD4十 helper T cell 
and CD8+ cytotoxic T lymphocyte responses take place against antigenic 
peptides processed from tumour antigens and presented by MHC molecules 
at the tumour cell surface. If the tumour cells are M H C class II negative, the 
class II recognition pathway can only function indirectly by presentation of 
tumour antigen peptides that are processed by MHC class II positive cells of 
the immune system, (macrophages and dendritic cells) that have taken up 
antigenic material from tumour cells. 
Surprisingly, destruction of MHC class II negative tumours by CD4十 cells 
that recognize tumour derived peptides in association with MHC class II 
molecules, can b e effective at the induction level and effector level 
(Greenberg, et oi., 1 9 8 8 ) . In an experimental Friend murine leukaemia virus 
induced tumour model in mice, tumour destruction was mediated via 
macrophages that had become tutnouricidal after activation by cytokines 
secreted by tumour specific CD4十 helper T cells (Greenberg, et oL, 1 9 8 8 ) . 
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However, CDS CTL recognizing tumour derived peptides in association 
with MHC class I molecules are the most powerful mediators of tumour 
destruction (Melief, 1991; Melief and Kast, 1991a,b). 
Adoptive therapy of murine tumours with T cells has been reviewed recently 
(Greenberg, et d” 1988; Melief, et oL, 1989; Melief, et d., 1991; North, et 
oL, 1989). In short, murine tumours induced by either RNA or DNA tumour 
viruses can be successfully eliminated by cloned CD8十 or CD4十 T cells. 
CD8 CTL clones are particularly effective, usually in the presence of 
interleukin-Z (IL'2). Complete elimination of large established tumour 
masses has been achieved in the case of Friend virus induced leukaemia in 
mice with cloned T cells and IL-Z (Greenberg, et d.’ 1988; Kast, et d” 1989; 
Melief et oL, 1989； Melief and Kast, 1990, 1991a,b; Kast and Melief, 1991; 
Melief, 1991). Further evidence comes from the report that mice depleted 
of either CD4 or CDS T cells by pretreatment with the respective depleting 
monoclonal antibodies (MAbs), developed tumours and metastases and died 
within 2 weeks. In vitro, CD4 T cells were required for induction of 
CDS tumour specific cytotoxic T cells (Schild, et d； 1987, 1989). These 
results thus demonstrate a role for regulatory CD4 T cells, which’ in 
cooperation with CDS T cells, take part in the in vivo induction of 
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protective anti-tumour immunity and tumour rejection. These findings will 
lead to possible therapeutic interventions in the anti-tumour immune 
responses. 
B lymphocytes are the only cells that are responsible for secreting 
antibodies. B lymphocytes derive from pluripotent hematopoietic stem cells 
in bone marrow that also generates myeloid and erythroid elements. Antigen 
specificity in each B cell clone is determined at the pre^ B cell stage and 
mature B cells express Ig receptors with the same specificity as that produced 
following differentiation into antibody secreting cells. A given antigen that 
can select a particular B cell clone triggers the activation process of the 
resting B cells into antibody secreting cells. And the overall process of 
activation- clonal expansion and differentiatioii of B cells is mediated by a 
number of signals interacting with cell surface receptors. These include 
antigen receptor (mlg), receptors for a variety of cytokines, including IL'2, 
IL'4, IL'5 and IL'6, and other regulatory receptors, such as Fc receptor, and 
cell'cell adhesion receptors (Mackay and Imhof, 1993; Clark and Lane, 
1991； Vitetta, et al., 1991). 
Apart from, the properties to bind antigen, mlg serves as a receptor for 
endocytosis and internalization of the bound antigen/mlg complex. This 
internalized antigen is degraded into peptides that form a complex with 
J • 
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Class II MHC antigens. This complex is transported to the cell surface, 
where it can be recognized by the antigen receptor (TCR) on the surface of 
antigen specific T cells. This explains why B cells can also act as an antigen 
presenting cell in the immune system. 
The particular antibodies which are produced against antigen expressed on 
the tumour cells may exist in the patient's serum or they may be raised in 
experimental animals by immunization with the tumour. Although cell-
mediated reactions are probably of greater significance in the defence against 
tumours, antibodies against tumour antigens which are detectable in 
autologous sera can recruit cells carrying Fc receptors, for instance, LAK 
cells and macrophages. Complement-dependent cytotoxic antibody is found 
in animals bearing lymphoid tumours if the tumour burden is not large. 
Antibody-dependent cellular cytotoxicity (ADCC) is demonstrable in some 
sera from patients with tumours. 
Although anti-tumour antibody response are generated during the course of 
tumour development, animal studies indicate that T cells play a relatively 
larger role in tumour rejection than B cells. However, antibody reactivities 
of patients to their own cancers can also be revealed by generating 
hybridomas from the patient's B cells. Most such monoclonals cross'react 
with other tumours and recognize intracellular antigens such as intermediate 
% 
j 
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filaments. Those antibodies that bound to the surface of the tumour cells 
reacted with carbohydrates on glycolipids (Lloyd, 1990). Also, one of the 
anti-tumour strategies at present makes use of the conjugation of specific 
monoclonal antibodies against tumour antigens and a toxin, which is termed 
immunotoxins, has been tested in animal system for anti'tumour activity 
with variable degree of success (Vitetta and Uhr, 1985). 
13.2 Macrophages 
Mononuclear phagocytes arise in the bone marrow and, after a brief journey 
through the blood as monocytes, imiiiigrate into the tissues where they 
become macrophages. This kind of cells, which share a cotnmon origin, 
morphology, and metabolism and function, is widely distributed in all tissues 
of the body and displays complex activities of maturation, proliferation and 
immigration in several tissues. 
Macrophages have an increased capacity for release of reactive oxygen 
intermediates (ROI) but do not actively secrete certain important molecules 
such as a cytolytic serine proteinase that leads to the destruction of tumour 
cells. Rather, primed macrophages have been prepared or primed for 
secretion of these molecules, when an appropriate stimulus is presented. 
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Responsive Macrophages Primed Macrophages Activated Ma crophages 
Capacities 
la - la 十+十 + la + + 
TFR十十十十 TFR • TFR • 
LFA-1 - LFA-1 ++十十 + + + + 
Secretion of CP and TNFa - Seer技ion of CP and T N F a • Secretion of CP and 
TNFa +十十十 
Secretion of ROI - Secretion of ROl + + + Secretion of ROI + + + 
Bind tumour ceils • Bind tumour cells 十十+十 Bind tumour cells 十十十十 
Fimctions 
Elevated Chemotaxis and Elevated Chemotaxis and Elevated Chemotaxis and 
Phagocytosis Phagocytosis Phagocytosis 
Proliferate Do not proliierate Do not proliferate 
Microbicidal Microbicidal 
Present antigen Kill tumour cells 
Figure 1.1 A model of macrophage activation for tumoricidal destruction. In this 
model, IFN-y primes macrophages and a second signal such as LPS converts them 
to the fiilly activated form. Note how the various capacities - such as expression of 
surface la molecules, of the transferrin receptor (TFR), or of LFA-1 and the secretion 
of important products such as a cytolytic protease (CP), TNF-a, or reactive oxygen 
intermediates (ROI) - vary with the stage of activation. (Adams, 1987, 1990) 
一. • 
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Moreover, primed macrophages are able to bind tumour cells in the absence 
of antibody. Fully activated macrophages are characterized by increase in 
secretion of cytolytic proteinase and TNF-a and, functionally, are activated 
for the destruction of tumour cells. 
The destruction of tumour cells by macrophages is a complex one. 
Mononuclear phagocytes are in fact capable of injuring neoplastic cells by 
four distinct mechanisms: cytostasis, slow antibody-dependent cellular 
cytotoxicity (ADCC), rapid ADCC, and the antibody i^ndependent form of 
cytolysis (macrophage-mediated tumour cytotoxicity). Each of these forms 
of tumour cell injury can be fulfilled as long as the macrophages are 
activated. The precise route of activation for each of these four forms of 
destruction is, however, quite distinct. Macrophage^mediated tumour 
cytotoxicity is effected only by cells which are fully activated. Cells able to 
perform rapid ADCC are cells which have a high capacity for the release of 
ROI. Cells activated for lysis by slow ADCC (which also depends on ROI 
as a principal destructive mechanism) are found as certain subsets of cells in 
the primed stages of activation. ADCC is mediated through Fc receptors 
found on the cell surface of macrophages. 
The most intensively studied mechanisms involved in activation of 
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macrophages have been those involved in the activation for macrophage^ 
mediated tumour cytotoxicity produced by IFN'y plus LPS (see section 1.3.6 
and figure 1.1). 
133 Natural killer cells 
Natural killer (NK) cells are defined as the cells that mediate natural non-
MHC restricted cytotoxicity. Starting from early 1970s, several investigators 
found that NK cells are spontaneously cytotoxic in vitro for some normal 
fresh cells, most cultured cell lines, immature hematopoietic cells, and 
tumour cells in a non-MHC restricted maimer. NK cells are distinguishable 
from T, B, and myeloid cells and NK cell differentiation takes place in the 
bone raarrow and net in the thy^nus. NK cells, therefore, represent a distinct 
leukocyte subset, possibly constituting a third lineage of lymphoid cells. 
FcRIII (CD16) is one of the surface receptors originally identified on NK 
cells, as in macrophages, neutrophils and a minor subset of T cells. Through 
their FcRIII (CD16), NK cells can interact with and lyse IgG antibody-
coated target cells. NK cells can lyse a variety of target cells, including both 
normal and tumour cells. However, different cells vary significantly in their 
sensitivity to NK cells. The lytic mechanism mediated by NK cells is not 
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completely understood, but it may involve secretion of granule content, 
including the pore'forming protein perforin. Osmotic lysis following insertion 
of perforin in target cell membrane is therefore probably involved in NK cell 
lysis, although other mechanisin including endonucleasc' induced 
fragmentation of nuclear DNA (apoptosis) may take place (Herberman, et 
d” 1986). 
The cytotoxic ability of NK cells can be increased several-fold by treatment 
in vitro or in vivo with various cytokines, particularly interferon-a (IFN-a), 
IFN-P and IL-2. IL'2 is also able to induce proliferation of NK cells in vitro. 
The NK cells responses to IL-Z are mediated by the binding of IL-2 to the 
IL'2 receptor expressed on NK cells. In vivo, both IL-2 and IFNs induce NK 
cell blast formation and proliferation (Trinchieri, 19B9). 
NK cells can display a lot of functions, including production of cytokines 
and natural resistance against microbial infection and tumour growth. In 
human studies, NK cells have been found to play a primary role in the 
resistance to virus infection (Welsh, 1986). 
NK cells are powerful producers of cytokines, including IFN'Y, tumour 
necrosis factor-a, granulocyte-macrophage and monocyte colony'Stimulating 
factors, and IL'3. Ligand binding to FcRIII (CD16) or treatment with IL-Z 
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induce transcription of cytokine genes and therefore cytokine secretion. 
Interaction of NK cells with certain target cells also induces cytokine 
production. 
Production of cytokines is probably the major mechanism by which NK cells 
regulate the adaptive immune system, and the hematopoietic system. NK 
cells have been shown to have both stimulatory and inhibitory effects on T 
and B cell response in vitro. In vivo NK cells have been demonstrated in 
experimental animals in rejection of bone marrow transplantation (Yu et a/” 
1992). 
Using experimental tumours, it was found that NK cells were able to destroy 
tumour cells in vivo and inhibit tumour growth. This inhibition of tumour 
growth depends on the level of susceptibility of the tumour cells to NK cell' 
mediated cytotoxicity and the level of NK reactivity of mice (Herberman 
and Holden, 1978; Karre, et oL, 1980; Riesenfeld, et d” 1980). 
Numerous experimental data showed that 90^ 99% of intravenously (IV) 
inoculated tumour cells were eliminated during the first 24 h. The small 
fraction of surviving tumour cells (often <0.1%) were then able to form, 
tumour metastases. Thus, NK cells play an important role in the 
intravascular elimination of tumour cells (Gorelik, et o/” 1982). 
y 
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Augmentation of NK cell activity could influence the rate of tumour cell 
elimination and metastasis formation. Cytotoxic activity of NK cells can be 
stimulated by pretreatment of mice with C. parvuruy poly I:C, probably 
through the induction of interferon production (Djeu, et oL, 1979; 
Herberman, et d” 1980). Treatment of mice with these agents was found to 
be related with an increase in the clearance of radiolabeled tumour cells 
from the pulmonary vasculature and a decrease in the number of the 
detectable experimental metastases (Gorelik, et oL, 1984). 
1.3.4 Lymphokines-activated killer cells 
Having exposed to exogenous activation stimuli, for example, interleukin 2 
(IL'2), come T lymphocytes and NK cells increase in me, become more 
granular, and more able to kill a wide spectrum of tumour cells, virally 
infected cells, and even some normal tissue cells. This kind of IL'2 activated 
cells is known as lymphokine一activated killer (LAK) cells. In studies using 
blood from normal human donors, the activities of NK cells and LAK cells 
are similar, because NK cells are the predominant precursors of LAK cells. 
LAK cells are defined as lymphocytes that mediate noii'MHC restricted 
cytotoxicity against various kinds of target cells following in vitro or in vivo 
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activation with IL-2 alone or in combination with other cytokines. Like NK 
cells, LAK cells are a source of multiple cytokines, such as tumour necrosis 
factor-a (TNF-a) and interferoivy (IFN-y). 
Adoptive transfers of LAK cells and IL-2 to tumour-bearing animals were 
effective in inducing the regression of established lung, liver, and 
subcutaneous metastases of carcinomas (Melder, et d., 1988; Mulle, et d., 
1984). To achieve therapeutic effects with LAK cells and IL-2, it is 
necessary to administer sufficient numbers of LAK cells and high enough 
concentrations of IL'2 and to reduce tumour burden by previous surgery or 
by including chemotherapy. In animal models, this form of therapy can be 
effective against a metastatic tumour if the tumour burden is reduced by 
other ineaiis. O R ihe other hitnci, 2 5 - 3 0 % of patients with, metastatic 
melanoma and renal cell carcinoma, unresponsive to conventional therapy, 
responded well to immunotherapy with LAK cells and IL'2 (Whiteside, et 
d., 1989, 1990). 
In conclusion, the lysis of NK cells is limited to mainly cultured cell lines. 
NK cells are less able to lyse fresh tumour cells, but LAK cells are broadly 
lytic and able to mediate the lysis of a variety of syngeneic, allogeneic and 
xenogeneic NK-resistant fresh tumour targets. 
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1.3.5 Tumour infiltrating lymphocytes 
In the late 1980s, much attention was paid to mononuclear cell infiltrates 
in and around tumour sites. For T lymphocytes recovered from those 
specimens by mechanical and enzymatic treatment of tumour mass, followed 
by subsequent density gradient centrifugation, the term "tumour infiltrating 
lymphocytes" (TIL) was used. The presence of TIL in tumour tissue is 
assumed to indicate a host response against the tumour. Though freshly 
separated TIL generally have low cytolytic activity against tumour target 
cells, further propagation in IL'2 may generate highly cytolytic effector cells. 
In some instances, TIL have shown to have specificity for the autologous 
tumour target cells (Topalian, et al” 1989). 
A recent report on 28 months clinical trial states tkat 23 of 55 meianoma 
patients responded to TIL therapy in terms of tumour regression, whereas the 
remainder were regarded as non-responders. This response rate was regarded 
as better than that observed using IL-2 alone. Lysis of tumour cells by TIL 
(which was not due to LAK cell activity) was significantly higher for 
responding patients than for non'responding patients (Aebersold, et at” 
1991). 
In most reports, the activity of TTL is described as highly cytolytic for a 
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broader range of fresh and cultivated tumour cells, resembling the broad 
activity of LAK cells. However, whether TIL are a special effector cell with 
a particular pattern of cytolytic activity and specificity is not fully 
understood. 
13.6 Cytokines 
Cytokines are generally regarded as low molecular weight proteins released 
by leukocytes that mediate host responses to infectious or inflammatory 
stimuli, as well as normal cell growth, differentiation and repair (Dinarello, 
et d” 1987). In addition, cytokines such as interleukin-l (IL4) are produced 
by nonimmune cells and can be induced by various environmental stress, 
ranging tiom UV or ionizing radiation, chiiiiges in oxygen tension to 
physical exercise. It has been shown that different cytokines have certain 
biological activities in common^  such as fever can be caused by IL-l, TNF-a, 
EFN'O, and IL'6. Moreover, a single cytokine can have multiple biological 
activities. Some cytokines are able to influence the synthesis or biological 
activities of other cytokines. Finally, naturally occurring inhibitors of many 
cytokines exist in the form of soluble receptors and receptor antagonists. 
Unlike hormones, which are carried by the blood stream over the whole 
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body, cytokines are mainly involved in local effects. Some do have systemic 
effects, IL'6 being the most notable, but the major physiological role of 
cytokines is short-range, within a few cell diameters. Most cytokines are 
produced only after activation of the cells, from which the production is 
short'lived, usually for only a few days. Likewise, the half life of cytokines 
themselves in circulation is also very short, which lasts for a few hours in 
the case of TNF-a in murine in vivo studies (Tsang, et oL, 1993). Typically 
cytokines are effective in the picogram (pg) to nanogram (ng) ml'^  range. 
Cytokines mediate their effects after binding to high affinity receptors on the 
cell surface. The affinity of these receptors is very high, in the 10'^  to 10'" 
molar range, which accounts for their potency. Receptors are usually present 
bi low Tibmbers, but can be subjected to a variable degree ot apreguktion 
upon cell activation. 
Certain compounds like Lipopolysaccharide (LPS) are found able to regulate 
the cell activities by enhancing or depressing the expression of receptors on 
the cell surfaces or simply by inducing the release of certain cytokines or 
both. As a matter of fact of the important role of cytokines in the overall 
imiruine response, the partial aim of this research is to find out whether the 
extracts of a traditional Chinese herb - Bupleuri radix can act as a potential 
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immunomodulator on cytokines regulation or not. 
Interleukin 1 (IL-l) was one of the earliest identified endogenous mediators 
of inflammation (Atkins, et oL, 1989). It is a highly pleiotropic cytokine 
released primarily from activated monocytes or macrophages. 
Lipopolysaccharide (LPS) can stimulate the release of IL'l. Among the 
immunological responses it produces are: fever, thymocyte proliferation, 
induction of lymphokine release by T cells, costimulation of B cell 
differentiation and proliferation, augmentation of NK-mediated cytotoxicity, 
induction of prostaglandin release, chemotaxis and tumour cell lysis by 
macrophages, induction of acute phase protein synthesis from hepatocytes, 
proliferation of bone marrow stem cells (Dinarello, 1984; 1989; 1991). It is 
now kiiowB that there are two distantly related DcWpectides (IL- la and ！L 
• V / iL ^ � 
Ip) with molecular weights of about 17,000 Daltons, each of which appears 
to possess all the biological activities previously ascribed to IL-l (Furutani, 
et al., 1985; March, et d” 1985; Saklatvala, et d” 1985; Oppenheim, et al,, 
1986). 
IL-1 receptors were first identified and characterized on an IL^l responsive 
T'cell line (Dower, et ol” 1987). It found that the IL-l receptor is an Mr 
80,000 cell surface protein. Subsequent studies revealed that IL'l receptors 
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are widely distributed on cells of many different lineages (Dower, et a/., 
1989), including a human B-cell line. However the IL4 receptors found on 
B'cell lines are of different molecular weight, i.e. Mr 60,000 (Matsushima, 
et d” 1986). The two forms of IL4 receptors are now termed as type I 
(p80) and type II (p60). It found that type I IL-l receptor is widely 
distributed on several cell types (McMahan, et al.，1991), whereas type IIIL-
1 receptor has been isolated from human and murine B-cell lines 
(McMahan, et oL, 1991). 
It has been shown that I H stimulates the release of factors that require in 
the growth and differentiation of cells associated with myeloid and lymphoid 
cell lineages in vitro. These include granulocyte colony stimulating factor 
CSF) and tnacrophage colony stimulating factor (M-CSF) by humsn marrow 
stromal cells (Fibbe, et al., 1988); granulocyte仙acrophage colony 
stimulating factor (GM'CSF) by human dermal fibroblast (Kaushansky, et 
al., 1988) and human peripheral blood lymphocytes (Hermann, et oL, 1988). 
Moreover, IL-1 plays a very important role in regulating the transcription of 
genes for Interleukin-Z (IL'2) and IL'2 receptor (IL'2R) (Hagiwara, et al., 
1987). IL'l also exhibits considerable effects on the clonal expansion of 
helper T cells (Greenbaum, et oi., 1988), which is in general thought as a 
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result through the increasing expression of IL'2 and IL-ZR genes. 
Interleukin 2 (IL-Z) is a glycoprotein of 15.5kDa. The major producers of 
IL-2 are activated T cells, although B cells can also be induced to secrete 
this cytokine after in vitro stimulation with anti^ immunoglobulin antibodies. 
Resting lymphocytes do not secrete IL-Z but activation through the antigen 
receptor leads to the induction of both IL'2 and interleukin-2 receptor (IL-
2R). In the mouse, it is the Thl subset which secretes IL'2 together with 
IFN-y, TNF-p, IL'3 and GM-CSF. Murine Th2 subset does not appear to 
secrete IL'2. 
The major function of IL-2 is the activation of a number of cells in the 
immune system, including helper T cells, cytotoxic T cells, B cells, 
macropliages, NK ceils, LAK precarsors tnxd liitiicur infiitrating lymphocytes 
(TIL). IL'2 can act both as a paracrine and autocrine growth factor. 
Autocrine stimulation enables rapid clonal expansion of antigen-activated 
cells. Regarding the action of IL'2 on T cells themselves, other cytokines 
such as IL'4 and IL'5 are induced to be secreted Also, activation of 
monocytes by IL'2 induces IL'l secretion, enhances monocyte, mediated 
cytotoxicity, promotes proliferation of macrophage precursors, and increases 
phagocytosis. The NK response to lL-2 is characterized by IFN'y production, 
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proliferation, and increased cytolytic activity. 
Practically, IL-I has been used in tumour iminunotherapy, either IL-Z alone 
or in combination with in vitro activated LAK cells. The potential for IL-2 
as a cancer treatment is based on activation of cells which are cytotoxic to 
the tumour and on the induced release of cytotoxic cytokines. For instance, 
IL'2 is used to generate highly cytolytic TIL in vitro, which may exhibit 
more potent anti-tumour effects in vivo when returning to the body. 
IL-2 receptor is present on activated 丁 cells. It is composed of the IL-2Ra 
and IL'ZRp subunits, which altogether exhibit a much greater affinity for 
2 than either subunit alone. In resting human T cells, the IL'2Ra gene is 
transcriptionally silent. However, this gene is rapidly induced following 
antigen or mitogen stimulation. Likewise, resting T cells express low levels 
of IL'2Rp’ which increase following T cell activation. IL'2 receptors present 
on NK cells and resting T cells are capable of internalizing IL'2 and 
transmitting intracellular signals, which give rise to the activation of the 
cells. 
Granulocyte-macrophage colony stimulating factor (GM'CSF) was initially 
defined as a growth factor capable of supporting the clonal development of 
normal granulocyte-macrophage stem cells in vitro. The major producers of 
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GM'CSF are activated T cells, monocytes, fibroblasts and endothelial cells. 
GM'CSF synthesis are induced by a number of agents such as LPS, IFN-y, 
TNF-a, IL4, phorbol esters and lectins. 
GM'CSF has a broad range of functions including action as a growth and 
survival factor, and as an enhancer of the function of mature blood cells. 
GM'CSF acts directly as a growth factor for monocyte, granulocyte and 
eosinophil progenitors. It stimulates the production of neutrophils and 
enhances the function of these cells in the immune responses, especially 
strengthening the ability of neutrophils to kill antibody-coated tumour cells 
and to phagocytose bacteria, parasites and yeast. Biological effects of GM-
CSF in vivo show that it is a potent stimulator of hematopoiesis in human, 
so it is used as a therapeutic agent in bone mcirrow transplantation. 
Interferon-y (IFN-y) is an inducible cytokine, which is produced in 
lymphocytes only, i.e. T cells and NK cells. 丁 cells are apparently the major 
source of IFN-y under most circumstances. Of the subpopulations of T cells, 
helper T cells appear to be an important source of IFN卞 In the murine 
system, the Thl subset of helper T cells, not the Th2 subset, was found 
capable of producing IFN^y. 
IFN'Y production can be induced by various treatments leading to 
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lymphocyte activation. For T cells, the stimulus is obviously come from an 
antigen^presenting cell in association with MHC class II molecules to the 
antigen specific T cell receptor/CD3 complex on T cells. However, T cells 
can be activated by certain nonspecific mitogen such as PHA or 
concanavalin A (Con A). IFN-y is usually induced in coordination with 
2’ which is also coordinated with IL'l. The induction of IFN-y appears to 
be regulated mainly at the level of transcription. 
IFN'Y plays a very important role in the activation of monocytes or 
macrophages. Recent evidence shows that the macrophage activating factor 
(MAP) that primes macrophages for nonspecific tumoricidal activity is 
actually IFN-y. Treatment of human or murine macrophages with purified 
IFN-y at low ccriccntrations (<lng irJ 】）significantly enhanced their 
tumoricidal and microbicidal activities (Trinchieri and Penissia, 1985). 
Bacterial LPS or other agents may be required as second signals to trigger an 
optimal IFN'Y induced monocyte/macrophage activation. IFN^y stimulates 
monocytes or macrophages to synthesize TNF, and TNF in turn mediates the 
killing of some types of tumour cells by IFN^y activated 
monocytes/macrophages. Monocyte/macrophage activation by IFN^y is 
accompanied by an increased release of reactive oxygen intermediates (ROI), 
- " -. —' • .... ... — - . . - - 、 ， ‘ 、 -
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including hydrogen peroxide, which is the major mechanism, of killing of 
intracellular parasites. IFN-y is also known to enhance the expression of 
high^afFinity Fc receptors for IgG on monocytes or macrophages, and this 
action further shows that IFN-y are capable of having tumoricidal activity 
through ADCC. In addition, all IFNs, including IFN'a/p, can activate other 
cytotoxic effector cells, such as NK cells and cytotoxic T cells. 
Tumour necrosis factor-a (TNF-a) was so named because of its tumoricidal 
action against a range of tumour cells in vitro and in vivo. TNF-a appears to 
have a duality of function, i.e. it stimulates proliferative response in normal 
cells, but inhibits the proliferation of some tumour cell lines grown in vitro. 
For example, it is cytostatic or cytotoxic for murine L'929 cells, WEHI'164 
cf41sv etc. Ho^ ACver, the sensitivity to the cytotoxic action of TNF varies 
amongst different cell lines. For a number of human tumour lines, e.g. 
myelogenous leukaemia cell lines, the effects of TNF are cytostatic rather 
than cytotoxic (Heicappel, et oL, 1987). 
TNF'oc is mainly produced by activated macrophages, while T cells, B cells, 
NK cells, glial cells of the central nervous system and Kupffer cells of the 
liver also contribute a little production of it. 
The mechanism of TNF'mediated cytotoxicity is not completely understood 
• . . -. , . 
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Figure 1.2 Antitumour mechanism (Meager, 1990) 
(Adapted from reference) 
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as yet. It has been reported that TNF induces activation of arachidonic acid 
metabolism，and the pathway of conversion of arachidonic acid to 
prostaglandin results in the generation of free radicals, and DNA 
fragmentation is found on TNF-treated cells, which is probably due to 
exposure of themselves to the attack of free radicals. Possibly cells which are 
susceptible to TNF-mediated cytotoxicity are inefficient in removing 
potentially harmful free radicals. In contrast, the cytostatic/cytotoxic effects 
of TNF and IFN'y have been often demonstrated to be synergistic in certain 
tumour cells (Chen, et al., 1987). 
1.4 CARBOHYDRATES AS POTENTIAL IMMUNOSTIMULATING AGENTS 
In traditional medicine: extracts of certain ftingi and plants may be of 
assistance in the treatment of cancer. After investigation, many of these 
extracts have been found to possess potent immune stimulating activity. In 
many cases, this activity is due to complex carbohydrates, or in another 
term: polysaccharides. The polysaccharides are usually composed of glucose 
(glucans and lectinans), mannose (maimans), xylose (hemicellulose), 
fructose (levans) or mixture of these sugars. 
The polysaccharides act as immune stimulators through two distinct 
. . . . . . . . 
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mechanisms. Some activate macrophages, some activate T cells. Certain 
carbohydrates such as acemannan extracted from the pulp of the Aloe vera 
plant, act on both macrophages and T cells (Womble and Helderinan, 
1988). However, recent findings show that levans and certain 
polysaccharides extracted from traditional Chinese medicine, for example, 
Pseudostellaria heterophylla, also activate B cells (Wong, et d., 1992). 
Some mannans and glucans are very potent anti'cancer agents. The factors 
that determine whether a polysaccharide will have anti'tumour activity are 
still unclear. For soluble D^glucans, it has anti-tumour activity as long as it 
is linear in structure，without excessively long branches. 
In animal studies, glucan given i.v. can inhibit the growth of a murine 
alicgciLeic JicieiiGc^ciiiOiiia and increase tumour iiuu:rophagc populations. 
The glucan does not only decrease the number of hepatic metastases, but 
also the size of the primary tumour. If administered in combination with 
LAK cells, water soluble glucan can suppress the growth and metastasis of 
a reticulum cell sarcoma significantly (DiLuzio, 1983). The above therapy 
also increase splenic NK cell activity as well as Kupffer cell tumoricidal 
activity. 
Saccharomyces glucan probably exerts its anti'tumour effects by activating 
macrophages, including hepatic, splenic and peritoneal macrophages. The 
• • . . • • • . • . 
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macrophages are stimulated to produce soluble factors such as interleukin 1 
and tumour necrosis factor. Therefore, macrophages from glucan-treated 
animals have been shown to release factors that are cytotoxic to tumour 
cells. 
For the time being, it is evident that many complex carbohydrates, especially 
those extracted traditional herbs, can have inimunostimulating activity 
which may be of use in treating cancer (Yamada, 1989). However, the 
concepts about the stnicture^function relationship of this kind of 
polysaccharide is still very obscure. 
1.5 GENERAL PROPERTIES OF BUPLEURI RADIX (B .R. ) 
Buplpuri radix (柴藥 )， i s the dry root of Bupl^urum ckinens^ DC. or B, 
scorzonerifdium Willd. (Apiaceae) collected in spring and autumn. It is listed 
officially in the Chinese Pharmacopoeia and used in traditional Chinese 
medicine in treatment of influenza, fever, malaria and menstrual disorders. 
Its chemical constituents found as yet are emphasized on a series of 
triterpene saponins and sapogenins, named saikosaponins and saikogenins, 
which is mainly in the fat'soluble fraction, whereas the chemical 
constituents of the water-soluble fractions are seldom, reported (Seto, 1986). 
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2.1 MATERIALS 
2.1.1 Anirnals 
Inbred BALB/c and C57BL/6J were bred at the Animal House 
of the Chinese University of Hong Kong. They were fed by animal diet 
(Chow 5001, Rodent Laboratory) and tap water ad libitum. Female BALB/c 
and C57BL/6J mice of the same age (6-8 weeks old) were used in each 
experiment. 
2.1.2 Bupleuri radix (B. R.) 
Bupleuri radix were brought in the form of dry root from a local Chinese 
medicinal store (Hip Tak Wing, Ltd., located in Sheung Wan, Hong Kong). 
2A3 Buffers, ctdture media, and chemicals 
ACK Ivsing buffer 
8.29 g of NH4CI’ 1 g of KHCO3 and 37.2 mg of Na^EEJTA were 
dissolved in 800 ml distilled water, and pH value was adjusted to 7,2-
7.4 with 1 N HCl. The final volume was made up to 1 litre and then 
it was sterilized through a 0.2 filter and stored at room temperature. 
‘ •, . . . . . . . • • - . . . . . . . 一 . .. 
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Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 8.0g NaCl, 0.2g KCl’ U5g Na^ HPO ,^ 0.2g 
KHjPQj in 1 litre double distilled water. The pH of the solution was 
adjusted to 7.3 with O.IM NaOH or O.IM HCl. The solution was sterilized 
by autoclaving at 121^  C for 30 minutes. 
Hank's Balanced Salt Solution (HBSS) 
Hank's Balanced Salt powder (Sigma Chem. Co., USA) for 1 litre 
preparation was dissolved in 1 litre of double distilled water containing 0.3 5g 
sodium, hydrogen carbonate. The solution was adjusted to pH 7.2 and 
sterilized by membrane filtration. 
RPMM640 Medium 
RPMI-1640 powder (Sigma Chem. Co., USA) for 10 litres preparation was 
dissolved in 10 litres of double distilled water containing 21 g sodium 
hydrogen carbonate. The solution was adjusted to pH 7.2 and sterilized by 
membrane filtration. RPMI medium without supplement other than 1% 
antibiotics was usually used in washing cells and was designated as "plain 
RPMI medium". 
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Serum Supplements 
Foetal calf serum. (FCS) was obtained from. Gibco Co., USA. FCS was 
prepared as 50ml aliquots and stored at -20^ C until use. Heat'inactivated 
FCS (HIFCS) was prepared by incubating the aliquots at 56'C for 30 
minutes. FCS was usually used as a supplement to growth medium, for cell 
culture in vitro and the final concentration would be 10%. HIFCS, on the 
other hand, was used as a serum supplement for ceH'Oiediated cytotoxicity 
assays. 
Penicillin-Streptomvcin-Fungizone Solution (PSF) 
PSF was bought from Gibco, USA, Stock solution (lOOX) containing 10,000 
imits/ml of penirijlm G, 10,000 of streptofi?yc in i^ilphate and 300 
i^g/ml of amphotericin B was stored at C as 5 ml aliquots. Usually, 5 ml 
PSF stock was added to 500 ml RPMI medium containing 10% FCS or plain 
RPMI medium. The former was regarded as complete medium for cell 
culture, while the latter was regarded as complete RPMI. 
2-Mercaptoethanol Solution (2,ME) 
A 0.1 M stock solution of Z-ME (Sigma Chem. Co., USA) in sterilized 
• ‘ . 
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double distilled water was prepared and stored at - 2 0 � C as 200 |LI1 aliquots. 
Anti-fade Mounting medium 
100 mg p'phenylenediamine (Peking Chemical Works, China) was dissolved 
in 10 ml of PBS in the dark. 90 ml of glycerol was added and mixed 
thoroughly. The pH was adjusted to 8.0 with carbonate-bicarbonate buffer 
and the mixture was stored at -2(f C in the dark until use. 
Normal saline 
0 .9 . (w/v) NaCl dissolved in distilled water was used as normal saline, 
which can be stored at room temperature. 
Antibodies 
1. FITC'Conjugated rabbit and'rat IgG (whole molecule) antibody was 
bought from Sigma Chem. Co., USA and used at a dilution of 1:32 
in RPMI complete medium. 
2. Monoclonal rat antmouse interleukin^Z receptor antibody was 
purchased from Boehxinger Mannheim, Germany and used at a 
dilution of 1:40 in RPMI complete medium. 
, ' - ' • •‘ "• ‘ - .• , . ——.. ....’•*•�.-’. t-rr.", •‘ -••‘ „ 
Ch, Two Materials and Methods 41 
3. Monoclonal rat anti-mouse B cell - antigen monoclonal antibody 
(clone LR'l) was purchased from Serotec Co., UK and used at a 
dilution of 1:10,000 in RPMI medium. 
4. Monoclonal rat anti-mouse Thy 1.2 antibody (clone F7D5) was 
purchased from Serotec Co., UK and used at a dilution of 1:1,000 in 
RPMI medium. 
5. Rabbit anti-sheep red blood cell (SRBC) antibody (Hemolysin) was 
purchased from Sigma Chem. Co., USA and at a dilution of 1:40 in 
RPMI medium. 
Complement (C) 
rlptno'LO guinea pig coinplemer^rpiirrhiised ironi CedarlaTie Lab., 
Canada. The lyophilized powder was reconstituted with ice cold distilled 
water, sterilized by membrane filtration, distributed in 1 ml aliquots and 
immediately freezed at ' 20�C until use. 
Dyes 
1. May Gmnwald stain 
0.2 % (w/v) May Gmnwald stain (Sigma Chem. Co., USA) in PBS 
was used to stain rosettes in the assay of detecting Fc receptors. 
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2. Neutral Red Solution 
0.5% (w/v) neutral red (Sigma Chem. Co., USA) in normal saline 
was used as a vital dye for staining viable cells. 
3. Trypan Blue Solution 
0.1% (w/v) trypan blue (Sigma Chem. Co., USA) in PBS was used 
to access the viability of cells. 
4. A green fluorescent membrane dye, 3,3 '-dioctadecyloxacarbocyanine 
perchlorate (DIOC18 or D275) was purchased from Molecular Probes, 
Eugene, USA. It was used in the experiments of NK cell'inediated 
• cytotoxicity from a stock solution of 2.5 mg/ml prepared in dimethyl 
sulfoxide (DMSO) (Sigma Chem. Co., USA). 
5. Propidium iodide (PI) was purchased from Sigma Chem. Co., USA. 
The concentration of working solution of PI in NK cell-mediated 
cytotoxicity assay was 5 (ig/ml in PBS. 
Lvsing Solution for Peritoneal Exudate Cells 
1% sodium dodecyl sulphate (SDS) solution was prepared by dissolving Ig 
SDS in 100 ml double distilled water. 
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Scintillant 
In order to prepare 4.5 litres of Triton X - toluene scintillant, 0.4% (w/v) 
(�18g) 2,5'diphenyloxazole (PPO), 0.04% (w/v)(�1.8g) dimethyM,4'bis(2-(5-
phenyloxazol) benzene (POPOP), 3 litres of toluene and 1.5 litre of Triton 
X'lOO were mixed up by stirring overnight. 
(MethvU^H) Thymidine ('_H-TclR) Solution 
(Methyl'^H) Thymidine (2 Ci/mmol) was purchased from Amersham, UK. 
10 |aCi/ml working solution was prepared by diluting the stock solution with 
complete RPMI medium. For pulse labelling, 50 |Lil working solution was 
added to each culture well. 
Buffers for anion exchange using Diethvlaminoethvl Sephadex (DEAE 
sephadex A, 50) Anion Exchanger 
1. 10 mM sodium phosphate buffer was made by mixing 850 ml 10 mM 
NaCUNa2HP04 and 50 ml 10 mM NaCl-NaHzPO* , and the solution 
was adjusted to pH 8.0 by using NaH2P04 as a reagent for lowering 
pH value. 
2. IM sodium phosphate buffer was made by mixing 850 ml IM NaCK 
- • • " _ . . . 、 . . . ， - - , . • J • 
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NajHPO^ and 50 ml IM NaCl-NaHzPO* , and the solution was 
adjusted to pH 8.0 by using NaHzPO* as a reagent for lowering pH 
value. 
Buffers for Uronic acid (carbazole) assay 
1. Carbazole (Reagent A) - 125 mg of carbazole (Analar grade) was 
dissolved in 100 ml of absolute ethanol. It was stored in dark at 4 � C 
until use. 
2. Borate sulphuric acid reagent (Reagent B) - 2.39 g of sodium 
tetraborate decahydrate was dissolved in 250 ml of con. H2SO4. 
3. Glucuronolactone standards ‘ glucuronolactone was dissolved in water 
. s^ xvrM^d ^'ifh bep^osc tfciA in concentr^don of 1 mg/ni!-
Enzymes used in Tumour-infiltrating lymphocytes ajssay 
1. Trypsin was purchased from Difco Co., USA. The lyophilized powder 
was reconstituted with PBS to a concentration of 0.1% (w/v), and 
then sterilized by membrane filtration. 
2. The sterile form of collagenase was purchased from Sigma Chem. Co., 
USA. 
3. The sterile, lyophilized powder of dispase I, purchased from Boehringer 
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Mannheim Biochemica, Germany, was reconstituted with 1 ml sterile 
distilled water to a concentration of 5 tng/ml. The working solution 
was prepared by diluting the stock solution with PBS (Ca?十/Mg�十' 
free) to a concentration of 0.6 to 2.4 U/mL 
4. 1 vial of deoxyribonuclease I (DNase I), purchased from. Sigma Chem. 
Co., USA, was reconstituted with 1 ml of cold 0.15 M NaCl to give 
a stock solution with a concentration of 2,000 Kunitz units/ml. The 
stock solution was refrigerated until use. Before use, the working 
solution was prepared by diluting the stock solution to approximately 
80 Kunitz units/ml with cold 0.15 M NaCl, and sterilized by 
membrane filtration^ 
Mitogens 
Mitogens such as concanavalin A (Con A), and lipopolysaccharide (LPS) 
were purchased from the Sigma Chem. Co., USA. They were dissolved in 
PBS (1 mg/ml), millipore filtered and stored as 200 aliquots at '20�C 
until use. 
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Polymyxin B (PMB) 
Polymyxin B was purchased from Sigma Chem. Co” USA. 20 |ig/inl working 
solution was prepared by diluting the stock solution (2 mg/ml) with 10 % 
FCS and sterilized by membrane filtration before use. 
Reagents used in Lowrv method for protein determination 
1. Reagent C was prepared by mixing solution A (2% NazCO�in 0.1 N 
NaOH, solution B^  (1% CuSO )^ and solution B^  (2% 
sodium/potassium tartrate) in a ratio of 100 : 1 : 1. 
2. Folin Reagent 
Folin-Ciocalteu's phenol reagent from Merck is diluted Z-fold before 
use. 
Reagents for Phenol-Sulphuric method for CHO determination 
1. Concentrated sulphuric acid 
2. 5% (v/v) phenol was prepared by diluting phenol with double distilled 
water. 
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Red Blood Cells (RBC) 
Sheep red blood cells (SRBC) in Alsever's solution were purchased from 
Serotec Co., UK. 
Recombinant Interleukin 2 (rIL,2) 
Recombinant mouse IL-2 was purchased from Genzyme Co” USA. Stock 
solution (10,000 U/ml) was obtained by reconstituting the lyophilized 
powder with 1ml double distilled water, diluted to l,OOOU/ml with PBS, and 
then distributed in 200 pi aliquots and immediately freezed at -20�C until 
use. 
Mouse IFN-Y ELISA Kit 
Mouse IFN" ELISA kit was purchased from Genzyme Co., USA to assay 
for the quantity of IFN". 
Mouse GM-CSF ELISA Kit 
Mouse GM'CSF ELISA kit was purchased from Endogen Inc., USA to assay 
for the quantity of GM'CSF. 
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2.1.4 Cell lines 
Various murine cell lines used in this study were as follows: 
1. Fibroblast'like tumours: 
These include L929 (a transformed fibroblast cell line derived from 
C3H mice) and WEHI'164 (a methylcholanthrene-induced 
fibrosarcoma derived from BALB/c mice). 
2. Lymphoid tumours: 
These include MBL-Z (a Moloney leukaemia virus i^nduced T cell 
lymphoma of C57BL/6J mice), and YAC4 (a Moloney virus-induced 
T cell lymphoma of A/Sn mice). 
3. Macrophage-like tumour: 
This includes PU5'1.8 (a spontaneous macrophage'like tumour 
derived from BALB/c mice). 
4. Myeloid tumour: 
This includes Ml (a spontaneous myeloid leukaemia derived from SL 
mice). 
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5. Mouse carcinoma: 
EAT (Ehrlich ascites carcinoma) was derived from a solid line of 
Ehrlich carcinoma, an epithelial mammary carcinoma of mouse. It was 
first converted into ascitic form by Lowenthal in 1932 and afterwards 
this tumour model was widely used in cancer research. 
All the above cell lines (with the exception of fibroblast cell lines) were 
maintained in suspension cultures in complete RPMI medium and sub-
cultured every 4-5 days. On the other hand, the fibroblast cell lines are 
adherent cell lines, which were maintained in 25 cm^  tissue culture flask 
(Coming, USA) in 10 ml complete RPMI medium. When the cells formed 
一 an alrnost conflii户ru fnor.olayer, thev were tryosinhed with tryosm (0.1%)-
* * • 0 m, 
EDTA (0.04%) solution (Gibco, USA) for 3 minutes at 3f C, washed three 
times with complete RPMI medium and 10^  viable cells were seeded per 
flask. 
2.2 METHODS 
2.2.1 Extraction and Fractionation of Bupleuri radix (B.R,) 
The procedures for preparation of the crude extract of BR were shown in 
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Fig. 2.1. Dried roots of BR (100 g) were cut into small pieces and soaked in 
1 litre of double distilled water. After overnight soaking, they were boiled 
under reflux at 95。C for 4 hours. The supernatant was filtered successively 
through cheese cloth and Whatman number 1 filter paper by water suction 
and then refiltered through Whatman filter paper once more. The 
supernatant was then centrifuged in a high speed centrifuge (Beckman’ 
Model J2^21, USA) at 300 xg for 30 minutes. 
After centrifugation, the supernatant was concentrated to about half volume 
(500 ml) by evaporation. The crude extract was obtained by adding the 
supernatant to 9 volumes of 95 % ethanol followed by centrifugation at 
42,000 xg for one and a half hour. The precipitate was then dried up in a 
-fun*— ajpboi^ ^d o-^ '^ r^iight. Finally, the precicitate was redis^ o^lved in about 
I ^ / * Z. A. 
50 ml double distilled water and lyophilized. The lyophilized product was 
designated as the BR crude fraction. 
The crude extract of BR was fractionated by stepwise ethanol precipitation 
as shown in Fig. 2.2. Crude extract of BR (3 g) was dissolved in 100 ml 
double distilled water, an equal volume of 95 % ethanol was then added and 
stirred for a few minutes. The mixture was stood overnight and centrifuged 
at 42,000 xg for 30 minutes. The precipitate obtained was designated as 
BRzero. Then the supernatant was mixed wi th another equal volume of 95 
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% ethanol The mixture was then centriftiged at 42,000 xg for 30 minutes. 
The precipitate obtained was designated as BRI. Then the supernatant was 
further fractionated by the same procedure twice, and the supernatant from 
the last centrigagation was concentrated to about 100 ml by rotary 
evaporation, and then lyophilized. Altogether, the procedures of stepwise 
alcohol precipitation give rise to BR^ero, BRI, BRII, BRIII, and BRIV. 
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Cut 100 g of Bupleuri radix into small pieces 
Soak in 1 litre double distilled water overnight 
y 。 
Boil under reflux at 95'C for 4 hours 
y 
Centrifuge at low speed (300 xg’ 30 mins) 
Concentrate the supernatant to half volume by evaporation 
Precipitate w i th 9 volumes of 95% ethanol w i th continuous stirring 
Y 
Stand overnight y 
Centrifuge at high s p e ^ (42,000 xg, 90 mins) 
Collect and dry the precipitate 
¥ 
Redissolve the p rec i ^a te in distilled water 
Lyophiiize for 3 days 
y 
Crude extract of BR 
Figure 2.1 - Chart for hot water extraction method 
. “ 
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3 g crude extract of BR dissolved 
in 100 m l distilled water 
V 
Centrifuge 令t very low speed (100 xg, 5 mins,) 
Supernatant + same volume of 95% Et〇H 
wi th st irr ing for a few minutes 
Keep at for at least 2 hours 
V 
Centrifuge at high speed (42,000 xg, 30 mins.) 、 
Precipitate Supernatant + same volume of 
(fraction zero) 95% E tOH 
^ 、 
Precipitate Supernatant + same volume of 
(fraction I) 95% EtOH ^ 、 
Precipitate Supernatant + same volume of 
(fraction I I ) 95% E t O H 
Precipitate Supernatant evaporated to 
(fraction I I I ) 100 ml and then lyophilized 
(fraction IV) 
Figure 2*2 • Chart for stepwise alcohol precipitation 
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2.2,2 Purification of Bupleuri radix (B.R.) 
1st step - By Gel Filtration 
Fraction BRI of Bupleuri radix was purified by gel chromatography using G-
100 sephadex (Pharmacia, USA) packed in a column (2.5 x 100 cm) 
designed for standard liquid chromatography of macromolecules (Model 
XK50, Pharmacia). Refractive index (RI) spectrum was used to detect the 
presence of successive fractions eluted from the column. Fractions collected 
were lyophilized for 3 days. The first eluted fraction was designated as BRIa; 
while the second eluted fraction was designated as BRIb. 
2nd step - By Ion Exchange Chromatography 
Fractions BRIa and BRIb were further purified by DEAE sephadex A-SO 
anion exchange chromatography. 1 g of DEAE sephadex was added to 300 
ml 10 mM sodium phosphate buffer and allowed to swell at 4。C overnight. 
The slurry was transferred to a 30 ml'Syringe with glass wool at the bottom. 
The column (2.5 x 7 cm) was packed and further washed by 100 ml 10 m M 
sodium phosphate buffer. The sample (BRIa or BRIb) in a concentration of 
100 mg/ml sodium phosphate buffer was applied to the top of the column. 
The elution rate was adjusted to 1.6 ml/min. by using a clip at the outlet of 
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the column. Then the eluent was collected in test tubes in about 10 ml per 
tube. C H O content of each tube was assayed by phenol sulphuric acid 
method (Dubois et o l ” 1956), and plotted in a graph, which was examined 
to see whether there was a peak present. When the first peak (fraction 
containing cations or neutral molecules) had faded away, I M sodium 
phosphate buffer was added instead of 10 m M sodium phosphate buffer, in 
order to elute the second fraction (fraction containing anions). Both 
fractions were concentrated by evaporation and then dialysed against double 
distilled water using a dialysis tubings wi th a cut off value lower than 1,200 
(Sigma Chem. Co., USA) for 1 week. Eventually, the samples were 
lyophilized for three days and the final products were obtained. From the 
anion exchange chromatography, BRIa was fractionated into BRIai and 
BRIaii, while BRIb was purified into BRIbi and BRIbii, in which both 
BRIaii and BRIbii were the acidic fractions. 
2.2.3 Characterization of Bupleuri radix 
2.2.3.1 Determination of Carbohydrate and Protein Contents: 
CHO contents of all fractions of BR were determined by phenol-
sulphuric acid method (Dubois et d” 1956) and O.D.^^q was 
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measured. 
Protein contents of all fractions of BR were determined by Folin" 
Lowry method (Lowry et d” 1951) and O . D . ^ was measured. 
2.23.2 Determination of Uronic acid content: 
This assay is based on the method of Bitter and Muir (1962) w i th 
modification. 1500 p i of reagent B was added to screw-capped 
tubes and cooled in ice. Then standard or test solutions (250 ^il, 
containing <20 ^ig uronic add/ml) were layered onto the surface 
of reagent B and allowed to diffuse for 10 min. The tubes were 
gently mixed, and then heated in a boiling water bath for 15 min. 
The tubes were cooied aLtcfwaids in an k ^ h ^ i and the 
absorbance was read at 525 nm. 
2.2.33 Treatment of BR fractions wi th scxiium periodate: 
In order to confirm whether the mitogenic activity of BR fractions 
was due to their carbohydrate content, the carbohydrate 
components of two most bioactive fractions (BRzero and BRI in 
a concentration of 4 mg/ml) were oxidized by chemical treatment 
‘ L- . • 
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with 0.02 M sodium periodate at C for 24 hours, and then 
dialysed in double distilled water using a dialysis tubing w i th a cut 
off value lower than 1,200 (Sigma Chem. Co., USA) for 1 day. 
The dialyzates obtained were lyophilized. 
2.2.3.4 Treatment of BR fractions or LPS with acetic acid: 
In order to examine whether the mitogenic activity of BR 
fractions was due to LPS contamination, BRzero and BRI (4 
mg/ml) or LPS (2.5 mg/ml) were boiled in 2% (v/v) acetic acid 
at 100® C for 90 minutes, and then dialysed in double distilled 
water using a dialysis tubing wi th a cut off value lower than 1,200 
(Sign)” Chero. Co., ITSA.) for 1 day Tine .^ia!y2ates obtained were 
lyophilized. 
2.2.3.5 LC50 of BR fractions determined by Brine Shrimp Bioassay: 
LC5Q of BR fractions were determined by Brine Shrimp Bioassay 
(Meyer et oL, 1982; Anderson et d., 1991). Sea water was 
prepared by dissolving 3.8 g sea salt in 100 ml distilled water, and 
poured into the hatching tank. After shrimp eggs were added to 
the covered side of the hatching tank, a lamp over the uncovered 
！L . - . 
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side was turned on. This was a way for attracting hatched shrimps. 
The cysts were allowed to hatch and become mature nauplii for 
2 days. 
Vials for testing were prepared in triplicate. For each BR fraction 
being tested, concentrations of 1000, 100 and 10 jLig/ml were set 
up. 
After 2 days, 10 shrimps were counted and transferred to each 
vial, and the volume of sea water in each vial was adjusted to 5 
ml. 24 hours later, the number of survivors was counted and 
recorded’ which was in turn analysed by a computer software 
called Finney for determining the LC，。values. 
2.2.3.6 Test for the heat stability of BR fractions 
BR fractions were dissolved in PBS (1 mg/ml) and heated at 
lOO'C for 30 minutes. Having cooled down to room temperature, 
each fraction was cocultured w i th 5 x 10^ mouse splenocytes at 
a final concentration of 500 fig/ml at 37^ C for 48 hours. After 
incubation, the cultured cells were given a 6'hour pulse w i th 0.5 
^Ci/well ^H'TdR and radioactivity incorporated was determined 
• • • . -
, • 
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by a p'sdnti l lation counter (Beckman, USA). 
2丄 4 I n v ivo Drug Treatment 
In all of the in vivo assays, BR fractions were dissolved in PBS and 
administered by injection intraperitoneally. The average body weight of mice 
used was 25 g. 
2,2-5 Isolation and preparation of cells 
2.2.5.1 Splenocytes 
The method described by Hung (1987) was followed with minor 
modification. After the mice (BALB/c) were sacrificed by cervical 
dislocation, the spleens were removed asepticaily. Tiiey were OIL 
into pieces wi th a pair of fine scissors and pressed gently through a 
sterile 60 mesh stainless steel sieve with a plunger of 10 ml sterile 
plastic syringe. The cell suspension was centrifuged at low speed 
(100 xg, 20 seconds) in order to remove large cell clumps and 
debris. The resulting cell suspension was further centrifuged at 400 
xg for 5 minutes, and any observable white debris embedded in the 
cell pellet was removed by a P'200 autopipette (Gibson, France). 
鄰.’礼-- .-••‘.-, -_‘•.-.—— •_.. ---- ... ” ... 厂‘-
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The remaining cell pellet was resuspended in 10% FCS. 
2.2.5.2 Thymocytes 
Same as above, the mice were sacrificed by cervical dislocation, 
however, thymus were removed instead. They were processed same 
as the procedure tnentioned above for the preparation of splenocytes. 
2.2.5.3 Peritoneal Exudate Cells (PEC) 
The mice were sacrificed by exposure to anaesthetic ether, and 
placed ventral side up on a clean surface. The abdominal region was 
dampened with 70 % alcohol. The abdominal skin was lifted upward 
and a transverse incision along the midline was cut wi th a pair of 
sterile scissors. Then, the fiir was stripped back with the fingers to 
let the abdominal wall expose. 
A 5 ml syringe and a 20'gauge needle were used to inject 5 ml of 
cold HBSS into the abdominal cavity. Once the peritoneal cavity 
became distended, the abdomen was gently massaged wi th the 
fingers to ensure maximum suspension of cells. The fluid was 
transferred to a sterile 50 ml centrifuge tube kept on ice. The 
peritoneal cavity was washed once more with 5 ml cold HBSS. 
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The centrifuge tubes were centrifuged at 400 xg for 5 min. at 4。C, 
and the cell pellet obtained was resuspended in 10% FCS. 
2.2.5.4 Removal of RBC and dead cells using the one-step gradient method: 
The splenocytes were resuspended in complete RPMI and distributed 
into IZ-ml centrifuge tube (0.54 x 10® cells/4 ml/tube). 3 ml Ficoll-
Paque solution (Pharmacia LKB, USA) was layered under the cell 
suspension by placing t ip of pipette at bottom of tube, and slowly 
letting the solution flow under the cell suspension. The tubes were 
centrifuged at 800 xg for 15 minutes at room temperature. Viable 
lymphocytes were collected at the interface between the two layers. 
The cells were washed twice wi th complete RPMI and lastly 
resuspended in 10% FCS. 
2.2.5.5 Removal of RBC from spleen cell suspension: 
The spleen cell suspensions were centrifuged at 400 xg for 5 minutes 
at 4。C to form a pellet, which was then resuspended in A C K lysing 
buffer (〜5 ml buffer per spleen). The mixture was incubated for 5 
minutes at room temperature wi th occasional shaking. Then the 
lymphocytes were spun down at 200 xg for 10 minutes. The cell 
• • - . ' • • ‘ 
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pellet was washed again wi th complete RPMI and resuspended in 10 
% FCS. 
22.6 Assays for the Immunomodiilatxxry Activities of Bupleuri radix 
2.2.6.1 In vitro Mitogenic assay 
Splenocytes obtained from above were diluted wi th 10 % FCS to 
a concentration of 5 x 10^ cells/ml and 100 of i t was seeded 
into each well of a 96«^well flat'bottomed microtiter plate (Nunc, 
Denmark) together wi th different concentartions of BR fractions 
in a final volume of 0.2 ml 10 % FCS. The cultures were 
incubated in a humidified 5% CO! - 95% air incubator at 37。C 
for 48 hours. The cells were then pulsed wi th 0.5 uCi ^H-TdR per 
well for an additional 6'hour incubation, prior to cell harvesting 
onto glass fibre filters (Flow Lab., UK) using a semi-automatic 
Titertek cell multiharvester (Flow Lab” UK). The incorporated 
radioactivity was counted in a liquid scintillation counter 
(Beckman, USA). Incubations were usually done in quadruplicates 
and cell proliferation, as measured by ^H^TdR incorporation, was 
expressed as net counts per minute (cpm). 
f 
• • . 
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2.2.6.2 Ex vivo Mitogenic assay 
BALB/c mice in groups of three were pretreated wi th 0.2 ml PBS 
or 0.2 ml BR fractions (5 mg/ml) injection i. p. on day 0. The 
mice were sacrificed on day 3 and splenocytes were obtained as 
indicated before, and RBC were removed from the cell suspension 
using ACK lysing buffer. Lymphocytes (5 x were seeded into 
each well of a 96'Well microplate in a final volume of 0.1 ml 10 % 
FCS. The cells were then pulsed wi th 0.5 \iCi ^H^TdR per well for 
6'hour incubation in a humidified 5% CO! - 95% air incubator at 
37。C. The radioactivity incorporated was counted in a liquid 
scintillation counter. 
2.2.6.3 In vitro Mitogenic assay on BR fractions treated with periodate or 
acetic acid: 
The assay mentioned here was almost the same as the in vitro 
mitogenic assay mentioned before, the only difference was the 
samples being used - BR fractions treated wi th periodate or acetic 
acid were used here instead 
Ch* Two Materials ami Methods 64 
2.2.6.4 In vitro Co'initogenic assay on BR fractions and Polymyxin B 
sulphate: 
The assay mentioned here was similar to the in vitro mitogenic 
assay mentioned before. 50 p i of BR fractions (125 ‘ 1000 |xg/ml), 
50 111 of Polymyxin B (20 fig/tnl) and 100 of lymphocyte 
suspension (5 x l ( f cells/ml) were co-cultured at 37。C for 48 
hours. After incubation, the on-going procedure was exactly the 
same as described before. 
2.2.6.5 Effect of BR fractions on lymphocyte sub-populations: 
Prior to mitogenic assay, splenocytes obtained from the mice were 
treated with the following reagents so as to deplete one of the 
lymphocyte sub'populations. 
1. To deplete murine T cells, 40 f i l monoclonal anti-Thy 1.2 
antibody was added to 2 ml splenocyte suspension (2 x 10? 
cells/ml) at a final dilution of 1:1,000. The mixture was then 
incubated at room temperature for 30 minutes. The cells were then 
spun down and resuspended in 2 ml guinea pig complement 
(diluted 1:5 wi th complete RPMI). After 45 min. incubation at 
r 丨丨 ‘ 
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37^C, cells were washed wi th plain RPMI for three times and 
adjusted to 5 x 10^ cells/ml in 10% FCS. The viability of the 
remaining cells was checked by trypan blue dye exclusion method. 
2. To deplete murine B cells, 60 |al monoclonal anti-mouse B cell-
antigen was added to 2 ml splenocyte suspension (2 x lO? cells/ml) 
at a final dilution of 1:10,000. The mixture was then incubated at 
room temperature for 30 minutes. The cells were spun down and 
resuspended in 2 ml guinea pig complement (diluted 1:5 wi th 
complete RPMI). After 45 min. incubation at 37^C, cells were 
washed with plain RPMI for three times and adjusted to 5 x 10^ 
cells/ml in 10% FCS. The viability of the remaining cells was 
checked by trypan blue dye e^ idxiziar^  ructhod. 
2.2.6.6 Hemolytic plaque assay: 
BALB/c mice in groups of three were treated wi th 0.2 ml PBS or 
0.2 ml BR fractions (500 |ig/inl) injection i. p. on day 0, 2 and 4. 
On day 2 afternoon, about 4 hours following the second injection, 
all the mice were immunized w i th 2 x ICf SRBC in PBS (0.5 ml 
injected i. p.). On day 6, the mice were sacrificed by cervical 
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dislocation. Splenocytes were obtained from these mice as the 
method indicated before. After checking the viability of the cells 
wi th 0.1% trypan blue solution, two cell concentrations of 1.5 x 
10^ /ml and 6 x 10^ /ml in RPMI medium were prepared for 
hemolytic plaque assay. These cell suspensions were kept on ice 
unt i l use. 
For each of the above group of mice, 4 Cunningham 
microchambers were set up. For each spleen cell concentration, 2 
microchambers were used for assaying the number of plaque 
forming cells (PFC) in duplicate. For each concentration of 
splenocytes, 100 was placed into each of the two wells of 
riiicrciitcT tray. To each well, 50 of 20% SRBC in RPMI 
medium and 50 JJ! of absorbed guinea pig complement (diluted 
1:2.5) were added. The suspension was mixed by gentle shaking. 
50 f i l of this mixture was introduced into the microchamber using 
an autopipette. The open edges of the microchambers were sealed 
by clipping into a molten paraffin wax. The microchambers were 
then incubated in horizontal position at 37。C for 1 hour. 
The no. of PFC was counted under an inverted optical microscope. 
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The result was expressed as the number of PFC per 10^ viable 
splenocytes for each group of mice. 
2.2.6.7 In vitro assay of T cell-mediated cytotoxicity: 
C57BL/6J mice in groups of three were inimunized w i th 2 x 10^ 
L929 cells in PBS (0.5 ml injected i. p.) on day 0. O n day 1, 3 
and 5, 0.2 ml PBS or 0.2 ml BR fractions (500 |ig/ml) was injected 
i. p. per mouse. The mice were sacrificed on day 7, splenocytes 
were obtained from these mice as the method indicated before, 
including the removal of RBC by Ficoll-paque gradient 
centrifiigation. 
On day 6’ one day before the mice were sacrificed. lO^ L929 cells 
(target cells) in 0.2 ml 10% FCS were seeded into each well of a 
96-well flat-bottomeci microtiter plate and incubated at 37^ C for 
24 hours in a CO〗 incubator. After incubation, the supernatant 
was flicked off and the cells, which was adherent to the bottom of 
the tray, were washed with 0.2 ml warm RPMI. Neutral red 
solution (0.1 ml) was then added to each well and the tray was 
further incubated at 37^ C for 20 minutes in COj incubator. After 
... r 
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incubation, the neutral red solution was flicked off and the stained 
cells were gently washed twice wi th warm RPMI. RPMI (0.1 ml) 
wi th 10% HIFCS was then added to each well, followed by 
addition of 0.1 ml of the above splenocyte suspension (1 x 10? 
cells/iiil)(for each group, the assay was done in quadruplicate). The 
cell mixtures were incubated at 37。C for 24 hours in CO〗 
incubator. 
After incubation, the medium together with the nonadherent cells 
were flicked off, and the stained L929 cells were washed wi th PBS 
twice. 1% SDS solution (0.1 ml) was added to each well and the 
tray was allowed to stand at room temperature for 1 hour. The 
absorbai^ ce of each well was rend at O.D^ ^^ j. using a niicroelisa 
reader. The result was expressed as % lysis of target cells according 
to the following formula: 
C ， T 
% lysis = X 100% 
C 
where C = mean O.D. of control wells (no effector cells was 
added) 
T = mean O.D. of wells containing splenocytes 
2.2.6.8 IL-1 assay: 
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Thymocytes from BALB/c mice were obtained by the method 
mentioned above and diluted wi th 10% FCS to a concentration of 
5 X 10^ cells/ml. 100 of thymocyte suspension, 50 p i of 
recombinant IL-2 (100 U/ml), and 2 ^il of 5 x 10。M 2ME 
solution were added into each well and cultured with 50 |Lil 10% 
FCS or BR fractions in 10% FCS (1 mg/ml) at 3 / C for 3 days in 
a 5% CO2 incubator. The cells were then pulsed wi th 0.5 |xCi ^H-
TdR per well for an additional 6'hour incubation. The 
radioactivity incorporated was counted in a liquid scintillation 
counter. 
2.2,6.9 IL-2 ass^： 
Splenocytes (5 x 10^) from BALB/c mice were cultured wi th 0.2 
ml 10% FCS or BR fractions in 10% FCS (62.5 - 500 ^ig/ml) at 
37^C for 2 days in a CO! incubator. Supematants were collected 
by spinning down the cells at 400 xg for 5 minutes, and were used 
for IL-2 assay. 
7 
The Con A blast cells were prepared from a 3'day culture of 10 
BALB/c splenocytes in 10 ml 10% FCS, Ig/ml Con A and 5 x 10'^  
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M 2'ME solution in a 25 cm^ tissue culture flask. After incubation, 
the Con A blast cells were washed three times wi th plain RPMI 
to remove any residual Con A and other secretory products. Viable 
Con A blast cells were obtained by centrifugation on Ficoll'paque 
gradient. The cells were then washed and resuspended in 10% FCS 
to a concentration of 5 x 10^ cells/ml. 
The above cell suspension (100 pi) was cultured wi th 100 j i l of 
supernatant prepared previously in a 96-well flat'bottomed 
microtiter plate at 37^ C for 18 hours in a CC\ incubator. Prior to 
cell harvesting, the cells were pulsed with 0.5 {iCi H 'TdR per well 
for an additional 6'hour incubation. The radioactivity incorporated 
was counted in a liquid scintillation counter. 
2.2.6.10 IL " ! receptor assay: 
0.5 ml of BALB/c splenocytes (2 x 10^ cells/ml) were cultured 
either wi th i) 0.5 ml 10% FCS or i i) 0.5 ml Con A (4 ^g/ml) or 
i i i ) 0.5 ml BR fractions (400 ^g/ml) or iv) 0.25 ml BR fractions 
(800 [ig/ml) and 0.25 ml Con A (8 pig/inl) at 3f C for 3 days in 
a CO2 incubator. 
•. 、、 
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Then the cells of each group were assayed for IL-Z receptor 
expression by the indirect itmnunofluorescent method as follows: 
For each group, 1 x 10^ cells were washed with cold complete 
RPMI and centrifuged at 300 xg for 10 minutes at C to obtain 
a pellet. The pellet was resuspended in 0.1 ml of diluted (1:40) rat 
anti'inouse IL-Z receptor IgG, and the mixture was incubated for 
30 minutes on ice. During incubation, the vial was agitated once. 
Then the cells were washed twice wi th cold complete RPMI. After 
centrifiagation, the pellet was resuspended in 0.1 ml of diluted 
(1:32) FITC-conjugated rabbit anti-rat IgG. The mixture was 
incubated at 37^ C for 1 hour in a shaking water bath. Thereafter, 
the cells were washed twice wi th cold complete RPMI and 
centrifuged at 300 xg. The cell pellet was resuspended in 0.1 ml 
anti'fade fluorescent mounting medium. A small drop of cell 
suspension was placed onto a microscope slide with coverslip on 
top. The no. of cells, which was visible as green rings, was counted 
under an incident U V light microscope. Moreover, a total of 200 
cells was counted under visible light, and the % of fluorescing ( IL, 
2 receptor positive) cells out of the 200 cells for each group could 
be calculated. 
- — - ^ r • ‘ 
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2.2.6.11 Murine GM^CSF assay: 
Splenocytes (5 X 10^) from BALB/c mice were cultured wi th 0.2 
ml 10% FCS or BR fractions in 10% FCS (62.5 ‘ 500 ^ig/ml) at 
37^C for 2 days in a CO] incubator. Supematants were collected by 
spinning down the cells at 400 xg for 5 minutes, and assayed by 
the GM^CSF ELISA kit. 
2.2.6.12 In vivo migration of macrophages: 
The method of Gervais et al, (1984) was used w i th slight 
modification. BALB/c mice in groups of five were either injected 
i.p. with 02 ml BR fractions (500 yig^ml) or an equal volume of 
PBS. 2 days later, PEC of each mouse were harvested and counted, 
and the volume of cell suspension ( in RPMI supplemented wi th 
10% FCS) from each mouse was adjusted to a fixed volume. 2 ml 
of the PEC suspension in 10% FCS was added to each well of a 6-
well flat'bottomed tray. After 3-hour incubation at 
incubator, the no. of non-adherent cells was counted, from which 
the number of adherent cells could be calculated. 
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2.2.6.13 Assay for the Fc receptor expression on murine resident PEC: 
BALB/c mice in groups of three were either injected i.p. w i th 0.2 
ml BR fractions (500 |ig/ml) or an equal volume of PBS. 2 days 
later, PEC (macrophages) of each group of mice were harvested 
and counted. 
SRBC were washed three times with PBS and the cell 
concentration was adjusted to 1 x 10^ cells/ml. A n equal volume 
of SRBC suspension and mouse IgG anti-sheep erythrocyte 
monoclonal antibodies (1:40 dilution) were mixed. The mixture 
was incubated at 3 / C for 30 minutes in a COj incubator. After 
incubation, the cells were washed three times with PBS. The 
tc^ukimt ceiis coated with suitibodies were teraied EA^ • 
0.1 ml of EAq (10® cells/ml) and 0.1 ml of macrophages from 
different groups (1 x 10^ cells/ml) were mixed in centrifuge tubes, 
and then centrifuged at 100 xg for 10 minutes at 4。C. The cell 
pellet, immersed in complete RPMI medium, was incubated for 30 
minutes at 4。C. After incubation, the supernatant was flicked off 
and the cell pellet was resuspended in complete RPMI. The cell 
suspension was smeared onto glass slides, dried in air, fixed in 
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methanol and stained wi th May Gmnwald/Giemsa. Macrophages 
wi th three or more adherent erythrocytes were termed rosettes. A 
number of 200 macrophages was counted under the optical 
microscope and % of resetted cells formed was calculated. 
2.2.7 Assays for the immunorestorative properties of Bupleuri radix 
2.2.7.1 In vitro mitogenic assay using aged mice: 
Splenocytes (5 x 10^) from BALB/c aged mice (14 months old) 
and normal mice (8 weeks old’ acted as a positive control) were 
obtained and cultured wi th different concentrations of BR fractior^ 
at 37。C for 2 days in a final volume of 0.2 ml. The cultures were 
pulssed for an aclditionai 6 hours with 0.5 \iCi 'H-TdR per weii, 
prior to cell harvesting. The radioactivity incorporated was counted 
in a liquid scintillation counter. 
2.2.7.2 In vitro mitogenic assay using tumour^bearing mice: 
The assay was almost the same as above (see section 2.2.7.1), 
splenocytes from EAT-bearing BALB/c mice were used instead (1 
X 10^ EAT cells/0.2 ml PBS /mouse were injected i.p. ten days 
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before the assay). 
2.2.8 Assays for the anti^tumour activities of Bupleuri radix 
2.2.8.1 In vitro cytostatic effect of BR fractions on murine tumour cell 
lines: 
Cells (5 X 10^) from, different cell lines at their logarithmic phase 
of growth were seeded into each well of a 96'weU flat-bottomed 
microtiter plate in 0.2 ml BR fractions (62.5 , 500 |xg/inl) or 0.2 
ml medium only. After incubation at 37^ C for 48 hours, the cells 
were pulsed wi th 0.5 j iCi ^H-TdR for an additional 6 hours. The 
cells were then harvested, and the radioactivity incorporated was 
counted in a liquM sdntiihticn co i^nter. In case of adherent cells. 
50 |xl of 1 N NaOH was added to each well so as to detach the 
adherent cells from the plastic surface immediately before cell 
harvesting. Results were expressed as % suppression wi th reference 
to the control. 
2.2.8.2 Effect of BR fractions on the growth of tumour cells in vivo: 
BALB/c mice in groups of five were either treated wi th 0.2 ml BR 
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fractions in PBS (500 jig/ml) or an equal volume of PBS injection 
i.p. per mouse on day 0, 1, 2, 3, and 4. On day 2 afternoon, 
subsequent to the administration of BR fractions in the morning, 
1 X 10^  EAT cells/ 0.2 ml PBS were injected i.p. per mouse. On 
day 9, the mice were sacrificed, and EAT cells in the 
intraperitoneal cavity were washed out wi th PBS and counted 
under the microscope. 
For MBL'2 cells, C57BL/6J mice were used instead. 
For WEHI-164 cells, BALB/c mice were injected s.c” and tumour 
weights were determined instead of counting cells in the final step. 
2.2.8.3 Effect of BR fractions on the survival of EAT-bearing mice: 
BALB/c mice in groups of twenty were either treated wi th 0.2 ml 
BR fractions in PBS (500 jig/ml) or an equal volume of PBS 
injection i.p. per mouse on day 0, 1, 2, 3, and 4. O n day 2 
afternoon, subsequent to the administration of BR fractions in the 
morning, 1 x 10^  EAT cells/ 0.2 ml PBS were injected Lp. per 
mouse. The mean survival time of each group and the mortality 
pattern of the tumour-bearing mice were determined. 
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2.2.8.4 Ex vivo induction of NK cell activity by BR fractions: 
The two colour fluorescent method described by Kroesen et d. was 
used with slight modification. BALB/c mice in groups of three were 
treated with 0.2 ml BR fractions (500 ^g/ml) or an equal volume 
of PBS injection i.p. per mouse on day 1, 2 and 3. On day 4, the 
mice were sacrificed, and splenocytes were obtained as the method 
indicated before. 
Y A C ' l cells (5 X 10^) were labelled overnight by incubation in 
culture medmin supplemented wi th D275 at a final concentration 
of 10 ligjml. The final concentration of DMSO during this 
labelling was approximately 0.4%. After labelling, the cells were 
washed once wi th plain RPMI to remove free label and v/ere ready 
for the cytotoxicity assay. 
Splenocytes (1 x 10^) were mixed with 1 x 10^ D275 labelled 
Y A C ' l cells in effector to target cell ratios of 100:1 and in a final 
volume of 1 ml 10% FCS. The cell mixtures were incubated at 3 / 
C for 4 hours in a CO! incubator. After incubation, the cells were 
spun down and resuspended in 50 ^il PBS containing 5 |ig/ml PL 
Immediately thereafter cell death was assessed by fluorescence 
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microscopy wi th a 495 nm filter permitting assessment of both 
green and red fluorescence. Each sample was counted twice in 
random order and each time 100 green fluorescent cells per sample 
was recorded. Dead target cells could be recognized as green/red 
double'fluorescent cells (green cytoplasm with a red nucleus), 
whereas living target cells were green mono-fluorescent. Living 
effector cells were invisible while dead effector cells were red 
mono-fluorescent. I n practice, the viability and cell types could be 
easily distinguishable. 
2.2.8.5 In vitro induction of LAK cell activity by BR fractions: 
BALB/c spicRocytes (5 x 10^ ) were cultured with BR fhxtkms (2CK) 
^g/ml) and/or r IL '2 (50 U/ml) at 37^ C for 3 days. Viable effector 
cells were obtained by Ficoll-paque gradient centrifiigation and 1 
X 10 cells were added to 4 X 10^ W E H M 6 4 target cells and the 
mixture was incubated at 37^ C for 24 hours. After incubation, the 
cell suspension was flicked off and every well was washed twice 
with warm PBS. Neutral red solution (0.1 ml) was then added to 
each well and the tray was further incubated at 37。C for 20 
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minutes in CO] incubator. After incubation, the neutral red 
solution was flicked off and the stained cells were gently washed 
twice wi th warm PBS. 1% SDS solution (0.1 ml) was added to 
each well and the tray was allowed to stand at room temperature 
for 1 hour. The absorbance of each well was read at QD.5仲 using 
a microelisa reader. 
2.2.8.6 In vivo induction of T I L by BR fractions: 
The method described by Elder and Whiteside (1992) was followed 
wi th minor modification. BALB/c mice in groups of five were 
injected s.c. w i th 1 x 10^ W E H M 6 4 cells in 0.2 ml PBS on day 
0, Starting from, day 18. 'he mke were esthc^ r '^ ^ r^e-^  wirK 0.2 liil 
BRIaii (10 mg/ml in PBS) or an equal volume of PBS i.p. for three 
consecutive days. O n day 23, the mice were sacrificed and 
dissected aseptically, and the neoplasm was removed and kept in 
cold HBSS. The tumour mass was cut into pieces wi th a pair of 
fine scissors and pressed gently through a sterile 60 mesh stainless 
steel sieve wi th a plunger of 10 ml sterile plastic syringe. 20 ml of 
cell clumps was mixed wi th an equal volume of enzymes cocktail 
(containing trypsin, collagenase, dispase and DNase, the 
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concentration of each enzyme depends on the tissue to be digested) 
and digested at 37。C for 1 hour in a shaking water bath. The 
digest was then filtered through several layers of sterile cheesecloth 
to separate large cell aggregates and undigested tissue from single 
cells. The filtered digest was washed three times wi th HBSS. The 
cell suspension was overlayered onto differential (75 and 100%) 
Ficoll'-paque gradients, which were formed by carefully overlayering 
100% (v/v) Ficoll'paque wi th an equal volume of 75% (v/v) Ficoll-
paque in HBSS. The above was centrifuged at 800 xg for 20 
minutes at room temperature. Cell fraction containing T IL was 
collected at the interface between 75% and 100% Ficoll-paque 
layers, and washed twice with HBSS. The number and viability of 
cells were determined by trypan blue exclusion test. Monoclonal 
anti-Thy 1.2 antibody (40 |xl) was added to 2 ml T IL containing 
cell suspension (2 x lO? cells/ml) at a final dilution of 1:1,000. The 
mixture was then incubated at room temperature for 30 minutes. 
The cells were then spun down and resuspended in 2 ml guinea pig 
complement (diluted 1:5 wi th HBSS). After 45 min. incubation at 
3 / C , cells were washed once wi th HBSS and resuspended in 2 ml 
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HBSS. The number and viability of the remaining cells were 
determined by trypan blue exclusion test again. For each group, the 
% of T IL in cell fraction could be calculated. 
2.2.8.7 In vitro induction of macrophage-niediated cytostasis on tumour 
cell lines: 
Resident macrophages from normal BALB/c mice were obtained 
from peritoneal cavity. 50 j i l of macrophage suspension (1 x 10^ 
cells/ml), 100 ^il of L929 cells (5 x 10^ cells/ml) and 50 ^il of BR 
fractions (62.5 '250 |ig/ml) were co-incubated in each well of a 24' 
well plate at 37^ C for 48 hours. The cell mixtures were pulsed 
- with a s 终Ci ^ H TdK ( in 200 d RPMI) per weii for an additioiiai 
6'hoiir incubation, prior to cell harvesting. The radioactivity 
incorporated was determined using a liquid scintillation counter. 
2.2.8.8 In vitro induction of macrophage-mediatecl cytolysis on tumour cell 
lines: 
The tumour cells (any adherent cell line) were cultured in a 75 
cm^ tissue culture flask unti l 50% confluent. The culture 
Clu Two Materials and Methods 82 
supernatant was discarded and replaced wi th fresh medium 
containing 2 }iCi/ml ^H^TdR. The cells were cultured at 3T C for 
24 hours. After incubation, the ^H-TdR containing medium was 
discarded, and the culture was washed three times to remove 
unincorporated label. Fresh medium, was added, and the cell 
culture was incubated at 3 / C for a further 4,6 hours in order to 
reduce spontaneous release of label during the assay. The cells were 
then harvested and resuspended at 4 x 10^ viable cells per ml. 
Resident macrophages from BALB/c mice were obtained from 
peritoneal cavity. Macrophages (2 X 10^), labelled target cells (2 x 
104) and different concentrations of BR fractions (0.5 and 1 
mg/ml) were CO-incubated in a fkml volume of L 5 mi at 37^ C tor 
48 hours. After incubation, the cell suspensions were centrifuged. 
at 200 xg for 10 minutes to remove cell debris and 0.2 ml of the 
.-.I 
culture supernatant was transferred and added to 5 ml of 
scintillant. The radioactivity release was determined using a liquid 
scintillation counter. 
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2.2.8.9 Murine IFN-y assay: 
Splenocytes (5 x 10^) from BALB/c mice were cultured with 0.2 
ml 10% FCS or BR fractions in 10% FCS (62.5 - 500 ^ig/ml) at 
37^C for 2 davs in a CO2 incubator. Supematants were collected 
by spinning down the cells at 400 xg for 5 minutes and were 
assayed by IFN-y ELISA kit. 
2.2.9 Statistical analysis 
The data were analysed by a computer software called Instat (Graphpad, 
USA), and the results were expressed as the arithmetic mean 土 standard 
error of means (x + S.E.M.). Student^s t'distribution [t=(x'| i)/S] was used to 
esdmate the confidence iiUervai in group comparison. Ncrmaiiy P<0.05 was 
accepted to indicate there is a significant difference between the groups. 
J 
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3.1 RESULTS 
3,1.1 Exti'action and fractionation of Bupleuri radix 
Water-soluble fractions of Bupleuri radix were extracted by hot water method 
and stepwise ethanol precipitation. These fractions are termed BR zero, BRI, 
BRII and BRIII, wi th molecular weights in descending order; whereas BRIV, 
the last fraction, mainly contains water-insoluble substances. 
3丄2 Purification of Bupleuri radix 
Amongst those fractions extracted from Bupleuri radix, BRI exhibits the most 
potent effect on lymphocyte proliferation (via mitogenic assay) and in vivo 
cytostasis of tumour cells. As a result, it was chosen to undergo further 
purifioition. 
BRI was purified by gel chromatography using G'lOO sephadex. Two 
fractions were obtained by eluting wi th water. The first fraction eluted was 
larger in molecular size, and designated as BRIa, whereas the second fraction 
eluted was smaller in molecular size, and designated as BRIb (Fig. 3.1). 
Then, BRIa and BRIb were further purified by anion exchange 
chromatography using DEAE sephadex by means of their charges. The 
polarity of the first fraction eluted (BRIai or BRIbi) was neutral or less 
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Fig. S.I Sephadex gel chomatography of BRI fraction 
BRI was fractionated by gel chromatography using G-lOO 
sephadex. The eluted fractions were detected by refractive 
index (RI) spectrum. Two fractions were detected, in which 
the first one was designated as BRIa, and the second one 
BRIb. 
/ 
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acidic, whereas the polarity of the second fraction eluted (BRIaii or BRIbii) 
was negative, or in other words, the second fraction eluted was the acidic 
fraction, containing anions. After performing anion exchange 
chromatography, BRIa and BRIb gave rise to BRIai and BRIaii, BRIbi and 
BRIbii, respectively (Fig. 3.2 and Fig. 3.3). 
3.13 Carbohydrate and brotein contents of BR fractions 
The carbohydrate and protein contents of BR fractions were determined by 
phenol-sulphuric acid method and Lowry method respectively. From the 
results (Table 3.1), the major component of BR fractions (except BRIV) was 
found to be carbohydrate. For the purified fractions (such as BRIai, BRIaii, 
, BRThi and BRIbi0. the curbohydrs^te contents are p-vqwA m t y oi so percent. 
Referring to Fig. 3.2 and Fig. 33, the protein component was eluted almost 
at the same time as the carbohydrate component in the ion exchange 
chromatography. It seems that the protein in each fraction is probably bound 
to the carbohydrate component. 
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Ffg. 3.2 DEAE sephadex ion exchange chromatography of BRIa 
fraction 
BRIa was fractionated by anion exchange chromatography 
using DEAE sephadex. The eluted fractions were detected by 
phenol-sulphuric acid method (O) and Lowry method (•)• The 
first fraction detected was termed BRIai, whereas the second 
fraction was termed BRIaii. 
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Fig. 3.S DEAE sephadex ion exchange chromatography of BRIb 
fraction 
BRIb was fractionated by anion exchange chromatography 
using DEAE sephadex. The eluted fractions were detected by 
phenol-sulphuric acid method (•) and Lowry method (•)• The 
first fraction detected was termed BRIbi, whereas the second 
fraction was termed BRIbii. 
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Table 3.1 Yield，carbohydrate and protein contents of various BR 
fractions 
Sample Yield (%) Protein (%) Carbohvdrate(%) 
BR crude 3.6 13.0 30.4 
BR zero 41.23 13.7 19.6 
BRI 24.26 7.7 31.0 
BRII 8.5 20.7 21.6 
BRllI 4.26 13.75 46.0 
BRIV 15,31 18.4 14.7 
‘ - — • . � 
BRIa 19,2 2.6 70.7 
BRIb 32.4 16.15 45.5 
BRIai 11.2 6.18 53.31 
BRlaii 62.3 10.77 52.62 
BRIbi 8.37 14.21 67.35 
BRlbii 50.02 30.38 66.08 
weight of purified fraction obtained 
Yield (%)= ； X 100% 
weight of mother fraction used 
Protein and carbohydrate contents were determined by Lowry 
method and phenol-sulphuric acid method respectively. 
Ch. Three Fractionation, Purification and Characterization 91 
3.14 Lack of cytotoxicity of Bupleuri radix to mouse sblenocytes 
The crude extract of Bupleuri radix, BRzero and BRI were assayed for their 
cytotoxicity towards murine splenocytes. Murine splenocytes, obtained by the 
method mentioned before, were adjusted to 5 x 10^ cells/ml in 10% FCS. 
Cells (5 X 10^) in 0.1 ml medium were then cultured with an equal volume 
of BR fractions (concentrations up to 1 mg/ml) in each well of a 96'weU 
microtiter plate at 37^ C for 2 days in a GO? incubator. After incubation, 
the viability of the splenocytes in each well was determined by trypan blue 
exclusion test. I t was found that neither the crude extract of BR, nor 
BRzero, nor BRI, have any significant cytotoxic effect on murine splenocytes 
(data not shown). 
3.15 LC^g of BR fractions determined by brine shrimb bioassay 
Brine shrimp bioassay is a simple, economic and reliable bioassay developed 
by Meyer et al. The bioassay makes use of brine shiimp instead of mouse in 
the determination of LC50. The LC50 values of BR fractions determined by 
brine shrimp bioassay were found to be greater than 1000 |ig/nil (Table 3.2). 
In view of these results, it is assumed that BR fractions show no toxicities 
to animals. 
T a b l e 3 . 2 B t r i n e s h r i m p toioassay 
Sample Concentration(iig/ml) v i a b l e D e a t h * "-^so ^ ^ 
Control — 3 5 O >1000pg/inl 
1 O O O 3 O 6 
BR —~ 
c r u d e 1 OO 2 >1000pg/ml 
2_0 3 0 1 j 
1 0 0 0 斗 8 o I 
BRzer -o 1 OO 36 。 >1000pg/ml 
1 O 54 O 
1 OOP O I 
B R I 1 OO 39 o >1000ng/ml 
2 I 
1 O O O 2 I 
B R I I 1 OO ^ o >1000ug/ml 
1 o 3 3 O 
1 OOP 5 
B R I 1 1 1 OO ^ o >1000tig/ml 
1 o 4 6 I 
1OOO 3 3 2 
B R I V 1 OO 4 0 o >1000iig/ml 
1 O 33 1 
1 OOO 4 1 4- I 
y r r — I nil HP . I I I ""iii.，in 丨 丨 • • i-ii-丨.• r ipwni^ ••政‘ “‘i 
B R I a 1 OO 33 2 >1000ug/ml 
l O 3J o 
1 OOO 26 6 I 
B R I b 1 o • 化 3 >lOOOiig/ml I 
1 o 4-e o 
1 OOO 3 3 t 
I BRIad . 1 OO ^ 2 >1000llg/ml I 
1 O 27 2 
1 O O O 2 I 
B R I a i i 1 OO 1 >1000tlg/ml I 
I 1_0 ^ 2 I 
I 1 O O O 3 4 6 I 
BRXtoi 1 OO ^ 5 >1000ng/ml 
1 ^ 3 I 
1 OOO 2 Q 5 I 
B R i t o i i 1 OO ^ 2 >1000pg/ml I 
1 O 2 7 2 I 
Hatched shrimps were cultured with various concentrations of BR 
fractions for 24 hours. Then the number of survivors was counted. 
The data obtained were analysed by the Finney computer software 
to determine the LC^q values. ^ L C j q values > 1000 pg/ml indicate 
‘ samples tested contain no toxic effect. 
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3.16 Heat stability of BR fractions 
BR fractions were cultured wi th 5 x ICf mouse splenocytes at a final 
concentration of 500 fig/ml at 37^ C for 48 hours. After incubation, the 
cultured cells were given a 6'hour pulse wi th 0.5 |xCi/well ^H-TdR and 
radioactivity incorporated was determined by a p'scintillation counter. I t was 
found that the mitogenic effect of the heat-treated BR fractions is almost the 
same as that of the untreated BR fractions (data not shown), indicating the 
BR fractions are resistant to heat. 
3.17 Uronic acid content of BRIai. BRIaii. BRIbi and BRIbii 
The purified fractions: BRIai, BRIaii, BRIbi and BRIbii, were taken to assay 
for their uronic acid content. I t was found that both BRIaii and BRIbii, the 
second fractions eluted from DEAE-sephadex anion exchange 
chromatography, contain larger amount of uronic acid (Table 3.3). 
3.2 DISCUSSION 
As you can see from Table 3.1, the yield of the purified fractions (BRIai, 
BRIaii, BRIbi and BRIbii) was low, partly because pigments of these 
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Table 3.3 Uronic acid assay 





1500 of reagent B was added to screw-capped tubes and cooled in ice. Then 
standard or test solutions (250 containing <20 ^.g uronic acid/ml) were layered 
onto the surface of reagent B and allowed to diffuse for 10 min. The tubes were 
gently mixed, and then heated in a boiling water bath for 15 ram- The tubes were 
cooled in an ice bath and the absorbance at 525 nm was read. 
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fractions were remained bound to the DEAE gel after eluting wi th large 
volume of high-salt reagent. However, these pigments could be released by 
10% formic acid and showed no mitogenic activity on murine splenocytes. 
For the determination of carbohydrate content by phenol-sulphuric acid 
method, the results showed low carbohydrate content. This could be due to 
this method is much more sensitive to monosaccharide, rather than 
polysaccharides. 
As to those acidic fractions (BRIaii and BRIbii), uronic acid content is quite 
high, this may probably related to their bioactivities, especially anti-tumour 
activity, which wi l l be discussed later. BRIaii contains the highest proportion 
of uronic acid amongst the purified fractions (〜21.3%), W i t h regard to Table 
3.1, nearly half of the carbohydrate content of BRIaii is uronic acid. Our 
results are consistent wi th a report on the immunopharmacology of Bupleuri 
radix. I t was reported that the bioactive polysaccharides contain 30% acidic 
polysaccharides (Zhang and Chen, 1989). 
Like other Chinese tonic drugs, Bupleuri radix is mild in action. From our 
studies, i t does not exhibit any toxicity towards the animals or the cells in 
vitro. 
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4,1 RESULTS 
4 . L 1 Effect of Bupleuri radix on the specific and nonspecific immtmity 
4.1.1.1 In vitro mitogenic activities of BR fractions 
Of the five BR fractions extracted, BRzero and BRI showed the 
most potent mitogenic activities on murine splenocytes (Fig.4.1). 
Fig. 4.2 and Fig. 4.3 show the mitogenic activities of the purified 
fractions of BR. The mitogenic activities of BRIa and BRIb were 
similar, but BRlbii seemed to be the potent mitogen amongst the 
most purified fractions, BRlaii was also a potent mitogen, but its 
immiinostimuktmg effect was slightly lower than that of BPJbii. 
4.1.1»2 Ex VIVO initogeiiic activities of 3R fraciions 
The results of the ex vivo mitogenic assay on BR fractions were 
quite different from that of the in vitro one. BRI showed a 
significantly higher response than BRzero and the control group 
(Fig. 4.4). For the purified fractions, the results were similar to the 
in vitro assay, i.e. both BRIa and BRIb showed a strong and 
significant mitogenic effect on murine splenocytes (Fig. 4.5). 
s 
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Fig. 4.1 In vitro mitogenic activites of BR fractions 
Murine splenocytes (5x10^ cells/well) from BALB/c mice were 
co-cultured with different concentrations of BR fractions. 
After an incubation period of 48 hrs., cultured cells were 
given a 6-hr. pulse with 0.5 i^Ci/well ^ H-TdR and radioactivity 
incorporated was determined. Vertical bars represent two 
standard errors. 
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Fig. 4.2 In vitro mitogenic activities of purified fractions of BR 
Murine splenocytes (5 x 10^ cells/well) from BALB/c mice were 
co-cultured with different concentrations of BR fractions. 
After an incubation period of 48 hrs” cultured cells were 
given a 6-hr. pulse with 0.5 i^Ci/well ^ H-TdR and radioactivity 
incorporated was determined. Vertical bars represent two 
standard errors. 
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F^. 4.3 In vitro mitogenic activities of purified fractions of BR 
Murine splenocytes (5 x 10^ cells/well) from BALB/c mice were 
co-cultured with different concentrations of BR fractions. 
After an incubation period of 48 hrs” cultured cells were 
given a 6-hr. pulse with 0.5 i^Ci/well ^ H-TdR and radioactivity 
incorporated was determined. Vertical bars represent two 
standard errors. 
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Rg. 4.4 Ex vivo mitogenic activities of BR fractions 
BALB/c mice in groups of three were pretreated with 0.2 ml 
PBS or 0.2 ml BR fractions (5 mg/ml) injection i. p. on day 0. 
The mice were sacrificed on day 3 and 5 x 10^ of the mouse 
splenocytes were seeded into each well of a 96-well microplate 
in a final volume of 0.1 ml 10 % FCS. The cells were then 
pulsed with 0.5 ^Ci ^H-TdR per well for 6-hour incubation in 
a humidified CO� incubator at 37^ C. The radioactivity 
incorporated was counted in a liquid scintillation counter. The 
differences between groups of control and treatment were 
determined by Student^s t-test. *P< 0.0005; **P< 0.0001. 
Vertical bars represent one standard error. 
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Fig. 4.5 Ex vivo mitogenic activities of purified fractions of BR 
BALB/c mice in groups of three were pretreated with 0.2 ml 
PBS or 0.2 ml BR fractions (5 mg/ml) injection i. p. on day 0. 
The mice were sacrificed on day 3 and 5 x 10^ of the mouse 
splenocytes were seeded into each well of a 96-well microplate 
in a final volume of 0.1 ml 10 % FCS. The cells were then 
pulsed with 0.5 )iCi ^H-TdR per well for 6-hour incubation in 
a humidified CO^ incubator at 3 7 � C . The radioactivity 
incorporated was counted in a liquid scintillation counter. The 
differences between groups of control and treatment were 
determined by Student's ^-test. *P< 0.005; 0.05; ***P< 
0.001. Vertical bars represent one standard error. 
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4.1.1.3 In vitro mitogenic activities of BR fractions treated wi th periodate 
Polysaccharides are assumed to be the bioactive component in BR 
fractions, thererfore BR fractions were treated wi th periodate which 
was used as an oxidizing agent to oxidize the polysaccharides. The 
treated fractions were assayed for their mitogenic activities. I t was 
found that the mitogenic activities of both BRzero and BRI 
dropped to a very low value (Fig. 4.6), it implied that the bioactive 
components are polysaccharides. 
4.1.1.4 In vitro mitogenic activities of BR fractions treated with acetic acid 
In order to confirm that the mitogenic activities of BR fractions 
were not due to LPS contamination, the BR fractions were treated 
with acetic acid, which would specifically decompose LPS, without 
altering the structure of polysaccharides. The treated fractions were 
assayed for their mitogenic activities. I t was found that the treated 
BRzero fraction nearly lost its mitogenic effect on murine 
splenocytes, while the treated BRI fractions could maintain its 
mitogenic activities to a certain extent (Fig. 4.8). This implied 
that BRzero was largely contaminated with LPS, whereas BRI was 
not. 
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Fig. 4.6 In vitro mitogenic activities of periodate-treated BR fractions 
BR fractions were pretreated with 0.02 M sodium periodate at 
for 24 hrs and then dialysed. Murine splenocytes (5 x 10^ 
cells/well) were co-cultured with different concentrations of 
periodate-treated BR fractions. After an incubation period of 
48 hrs., cultured cells were given a 6-hr. pulse with 0.5 
pCi/well ^H-TdR and radioactivity incorporated was 
determined. Vertical bars represent two standard errors. 
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F^. 4.7 In vitro mitogenic activities of acetic acid-treated LPS 
LPS was pretreated with 1% (v/v) acetic acid at lOO^C for 90 
.mins . and then dialysed. Murine splenocytes (5x10® cells/well) 
were co-cultured with different concentrations of LPS or acetic 
acid-treated LPS. After an incubation period of 48 hrs., 
cultured cells were given a 6-hr. pulse wit h 0.5 jiCi/well ^H-
TdK and radioactivity incorporated was determined. Vertical 
bars represent two standard errors. 
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Fig. 4.8 In vitro mitogenic activities of acetic acid-treated BR fractions 
BR fractions were pretreated with 1% (v/v) acetic acid at 
lOO^C for 90 mins. and then dialysed. Murine splenocytes (5 
X10® cells/well) were co-cultured with different concentrations 
of acetic acid-treated BR fractions. After an incubation period 
of 48 hrs., cultured cells were given a 6-hr. pulse with 0.5 
i^Ci/well ^H-TdR and radioactivity incorporated was 
determined. Vertical bars represent two standard errors. 
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4.1.1.5 In vitro Co-mitogenic assay on BR fractions and Polymyxin B 
sulphate 
This assay is based on the specific binding of polymyxin B sulphate 
to LPS. The binded LPS lost its mitogenic activities on murine 
splenocytes (Fig. 4.9). Hence, polymyxin B sulphate was used to 
co'incubate wi th the BR fractions in the mitogenic assay, in order 
to provide a solid evidence that LPS contamination did not occur. 
The results showed that the patterns of the mitogenic activities of 
BRIa or BRIb were almost the same, even if the polymyxin B was 
added (Fig. 4.10). 
4.1.1.6 Effect of BR fractions on lymphocyte sub-oopulations 
BRI was found to be a potent mitogen on B lymphocytes, rather 
than on T lymphocytes. However, there were still some significant 
mitogenic activities of BRI on T lymphocytes (Fig. 4.11). 
4.1.1.7 Primary humoral immune response to SRBC in BR-treated mice 
Both BRzero and BRI showed a good primary humoral immune 
response to SRBC, a T cell-dependent antigen; as the number of 
plaque forming cell was found to be increased significantly in mice 
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Fig. 4.9 In vitro Co-mitogenic assay on LPS and Polymyxin B sulphate 
50 III LPS (250 -1000 [ig/ml)，50 jil of Polymyxin B (20 i^g/ml) 
and 100 of lymphocyte suspension (5 x 10® cells/ml) were 
co-cultured at 37° C for 48 hours. After incubation, cultured 
cells were given a 6-hr. pulse with 0.5 jtiCi/well ^H-TdR and 
radioactivity incorporated was determined. Vertical bars 
represent two standard errors. 
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Fig. 4.10 In vitro Co-mitogenic assay on BR fractions and Polymyxin B 
sulphate 
50 i^l of BR fractions (250 - 2000 jig/ml), 50 [d of Polymyxin 
B (20 i^g/ml) and 100 i^l of lymphocyte suspension (5 x 10® 
cells/ml) were co-cultured at 3 7 � C for 48 hours. After 
incubation, cultured cells were given a 6-hr. pulse with 0.5 
jiCi/well ^H-TdR and radioactivity incorporated was 
determined. Vertical bars represent two standard errors. 
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Rg. 4.11 In vitro mitogenic activities of BRI on sub-populations of 
murine splenocytes 
Untreated, T cells depleted or B cells depleted murine 
splenocytes (5 x 10^ cells/well) were co-cultured with different 
concentrations of BRI. After an incubation period of 48 hrs., 
cultured cells were given a 6-hr. pulse with 0.5 i^Ci/well ^H-
TdR and radioactivity incorporated was determined. Vertical 
bars represent two standard errors. 
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treated wi th these BR fractions (BRzero: 275 PFC/10^ splenocytes; 
BRI: 300 PFC/106 splenocytes; Control: 170 PFC/10^ 
splenocytes)(Fig. 4.12). The degree of humoral immunity enhanced 
by BRIa and BRIb were similar to each other (around 320 PFC/10^ 
splenocytes)(Fig. 4.13). For the purified fractions, both BRIaii and 
BRIbii were the most outstanding fractions for enhancing the 
humoral immunity (more than 300 PFC/10^ splenocytes), the 
differences between groups of the control and treatment were 
statistically significant, wi th a P value lower than 0.01 (Fig. 4.14). 
• …，•-r-：- . 
4.1.1.8 Act ivi ty of cytotoxic T cells in BR-treated mice 
BRIbii was found to be a powerful agent in inducing CTL activity 
ex vivo, about 70% cytotoxicity on L929 cells. BRIaii also 
exhibited the above ability to a lesser extent, about 56% 
cytotoxicity on L929 cells (Fig. 4.15). The difference between 
groups of the control and BRIbii was statistically significant, w i th 
a P value lower than 0.01. 
4.1.1.9 Effect of BR fractions on IL - l - like factor production 
IL - l plays a very important role in regulating the transcription of 
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F^g. 4.12 Pr imary humoral immune response to SRBC in BR-treated 
mice 
BALB/c mice in groups of three were treated with 0.2 ml PBS or 0.2 ml BR 
fractions (500 ng/ml) injection i. p. on day 0, 2 and 4. On day 2 afternoon, 
about 4 hours following the second injection, all the mice were immunized 
with 2 X 10® SRBC in PBS (0.5 ml injected i. p.). On day 6, the mice were 
sacrificed. Splenoc^es (100 jil) in concentrations of 1.5 x ICT cells/ml or 6 x 
10® cells /ml were mixed with 50 i^l of 20% SRBC in RPMI medium and 50 … 
of absorbed guinea pig complement (diluted 1:2.5). The cell suspension in 
microchamber was incubated at 37°C for 1 hr. PFC were counted under the 
microscope. The differences between groups of control and treatment were 
determined by Student's /-test. *P< 0.05. Vertical bars represent one standard 
error. 
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Fig. 4.IS Pr imary humoral immune response to SRBC i n BR-treated 
mice 
BALB/c mice in groups of three were treated with 0.2 ml PBS or 0.2 ml BR 
fractions (500 ^g/ml) injection i. p. on day 0, 2 and 4. On day 2 afternoon, 
about 4 hours following the second injection, all the mice were immunized 
with 2 X 10® SRBC in PBS (0.5 ml injected i. p.). On day 6, the mice were 
sacrificed. Splenoc^es (100 fxl) in concentrations of 1.5 x ICT cells/ml or 6 x 
10® cells /ml were mixed with 50 of 20% SRBC in RPMI medium and 60 pi 
of absorbed guinea pig complement (diluted 1:2.5). The cell suspension in 
microchamber was incubated at 37®C for 1 hr. PFC were counted under the 
microscope. The differences between groups of control and treatment were 
determined by Student's t-test *P< 0.01. Vertical bars represent one standard 
error僅 
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F^g. 4.14 Pr imary humoral immune response to SRBC i n BR-treated 
mice 
BALB/c mice in groups of three were treated with 0.2 ml PBS or 0.2 ml BR 
fractions (500 ^g/ml) injection i. p. on day 0, 2 and 4. On day 2 afternoon, 
about 4 hours following the second injection, all the mice were immunized 
with 2 X 10® SRBC in PBS (0.5 ml injected i. p.). On day 6, the mice were 
sacrificed. Splenocytes (100 [lY) in concentrations of 1.5 x ICT celis/ml or 6 x 
10® cells /ml were mixed with 50 of 20% SRBC in RPMI medium and 60 i^l 
of absorbed guinea pig complement (diluted 1:2.5). The cell suspension in 
micrcxihamber was incubated at STC for 1 hr. PFC were counted under the 
microscope. The differences between groups of control and treatment were 
determined by Student's Uest. *P< 0.01; **P< 0.005. Vertical bars represent 
one standard error. 
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Fig. 4.15 Ac t i v i t y of cytotoxic T cells i n BR-treated mice 
C57BL/6J mice i n groups of three were immunized w i t h 2 x 
10^ L929 cells i n PBS (0.5 m l injected i. p.) on day 0. On day 
1，3 and 5，0.2 m l PBS or 0.2 m l BR fractions (500 ^ig/ml) was 
injected i. p. per mouse. The mice were sacrificed on day 7，0.1 
m l of splenocytes suspension (1 x 10? cells/ml) was added to 
each L929-coated well . L929 cells had been stained w i t h 
neut ra l red. The 96-well plate was incubated at 37。C for 24 
hrs. Some L929 cells were lysed and the remain ing cells were 
washed. SDS was added to lyse the cells and O.D.540 was 
measured by a EL ISA reader. The differences between groups 
of control and t reatment were determined by Student's ^-test. 
*P< 0.1; **P< 0.01. Vert ical bars represent one standard error. 
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genes for IL '2 receptor (IL-ZR) (Hagiwara, et d” 1987), so the 
presence of I L - l can induce the expression of more IL-ZR. As a 
result, IL-2 was employed to saturate the IL-ZR found on the 
surface of thymocytes. In the presence of I L ' l - like factor, more 
IL'2R was expressed and provided for the binding of IL-2 to the 
cells, which underwent more proliferation. Therefore, thymocyte 
proliferation can act as a measure of the quantity of IL - l " like 
factor in this way. 
As shown in Fig. 4.16, IL-1 - like factor production induced by 
BRIbii or BRIaii was significantly higher than the control 
• .. V,' - v'!"•戏. 、 V -
(P<0.0001 and P<0.005 respectively). 
4.1.1.10 Effect of BR fractions on IL-Z production 
BRIbii was able to induce the cultured splenocytes to produce IL-2, 
however the IL-2 production induced by BRIbii was much lower 
than that induced by con A (Fig. 4.17). 
4.1.1.11 Effect of BR fractions on IL,2R expression on murine splenocytes 
IL'2R expression on murine splenocytes was assayed by the indirect 
immunofluorescent method. I t was found that BRIbii alone showed 
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F^. 4.16 Effect of BR fractions on I L - l - l i ke factors production 
100 of thymocyte suspension (from BALB/c mice，5 x 10 
cells/ml), 50 ^il of recombinant IL-2 (100 U/ml), and 2 ^ i lo fS 
X 10-3 M 2-ME solution were added into each well and 
cultured w i th 50 j i l 10% FCS or BR fractions i n 10% FCS (1 
mg/ml) at 37^ C for 3 days i n a CO? incubator. The cells were 
then pulsed w i th 0.5 ^Ci ^H-TdR per well for an addit ional 6-
hour incubation. The radioact iv i ty incorporated was counted 
in a l iqu id scint i l lat ion counter. The differences between 
groups of control and treatment were determined by Student,s 
^-test. *P< 0.005; **P< 0.0001. Vert ical bars represent one 
standard error. 
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Fig. 4.17 Effect of BR fractions on IL-2 production 
Con A blast cell suspension (100 ^il) was cultured w i t h 100 jiil 
of supernatant of BR-treated lymphocyte culture i n a 96-well 
flat-bottomed microt i ter plate at 37^ C for 18 hours i n a CO。 
incubator. The cells were then pulsed w i th 0.5 ^iCi ^H-TdR per 
wel l for an addit ional 6-hour incubation. The radioact iv i ty 
incorporated was counted i n a l iqu id scint i l lat ion counter. 
Vert ical bars represent two standard errors. 
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an excellent effect on IL-ZR expression on murine splenocytes. 
Also, BRIbii showed a synergistic effect wi th con A on IL-ZR 
expression, about 67% of IL-ZR positive cells was found in this 
group, with a P value lower than 0.005 (Fig. 4.18). 
4.1.1.12 Effect of BR fractions on GM-CSF production 
Both BRIaii and BRIbii were able to induce cultured splenocytes 
to produce GM-CSF. A murine GM'CSF ELISA kit was employed 
to assess the GM-CSF released by these splenocytes. I t was found 
that both BRIaii and BRIbii could significantly induce GM-CSF ----
production. (Fig. 4.19). 
4.1.1.13 Immunopotentiating effects of BR fractions on macrophages 
4.1.1.13.1 In vivo migration of macrophages in BR-treated mice 
BALB/c mice were pretreated either wi th BR fractions or an 
equal volume of PBS. Two days later, PEC of each mouse 
were harvested I t was found that BRIbii or BRIaii 
administered in vivo significantly increased the influx of 
macrophages into the peritoneal cavity of the mice 
(P<0.0001 and P<0.005. respectively). (Table 4.1) 
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Fig. 4.18 Effect of BR fractions on IL-2R expression on mur ine 
splenocytes 
BALB/c mur ine splenocytes (1 x 10®) were incubated either 
w i th complete medium (Control), 2 j ig/ml Con A and /or 200 
Jig/ml BR fractions. The cultures were incubated for 72 hrs. at 
37° C. Viable cells were assayed for IL-2R expression by the 
indirect immunofluorescent method. The differences between 
groups of control and treatment were determined by Student's 
t'test *P< 0.05; **P< 0.01; ***P< 0.005. Vert ical bars represent 
one standard error. 
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Ftg. 4.19 Effect of BR fractions on GM-CSF production 
Splenocytes (5 x 1 0 ” from BALB/c mice were cultured with 
0.2 ml 10% FCS or B R fractions in 10% FCS (62.5 - 500 ^ig/ml) 
at 3 7 ^ C for 2 days in a COg incubator. Supematants were 
collected by spinning down the cells at 400 xg for 5 minutes 
and were assayed by the GM-CSF ELISA kit. Vertical bars 
represent two standard errors. 
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Table 4.1 In vivo migration of macrophages 
. • • • • « • . • . • . • . • • . . 
I 
PBS 2,87 ± 0.15 
BRIaii (*) 3.94 ± 0.17 
BRIbii (**) 4.16 ± 0.22 
BALB/c mice in groups of five were either injected i.p. with 0.2 
ml BR fractions (500 iig/ml) or an equal volume of PBS. Two days 
PEC o f e a c h 磁ou场e w e r e b a r v e s s t ^ d » The a b o v e pEC ^ u s p ^ n s i o n 
(2 ml) of each mouse in 10% FCS was incubated at 37^C for 3 hrs • 
The no. of non-adherent cells was counted, from which the no. of 
adherent PEC could be determined. The results were expressed as 
mean ± S.E.M. The differences between groups of control and 
treatments were determined by Student's t-test. *P<0.005: 
木本PCO.OOOl, 
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4.1.1.13.2 Effect of BR fractions on the Fc receptor expression on 
murine resident PEC 
The Fc receptor expression on murine PEC was assayed by 
means of SRBC preabsorbed wi th antibody, which termed 
EAq. EAq and macrophages from different groups of mice 
after treatment wi th PBS, BRIaii or BRIbii were mixed and 
incubated at for 30 mins. After staining the cells w i th 
May Gmnwald/Giemsa, the percentage of resetted cells for 
each group was examined under the microscope. The 
vB^centageSi o‘()ro孕etted cells for the groups of the control, 
BRIaii and BRIbii were found to be 38, 68 and 65 
respectively. The difference between groups were 
statistically significant (BRIaii： P<0.001; BRIbii: 
P<a005)(Fig. 4.20). 
4.1.2 Immunorestorative Properties of Bupleuri radix 
4.1.2.1 Effect of BR fractions on lymphocyte blastogenesis in aged mice 
Murine splenocytes from either aged BALB/c mice or normal mice 
were co-cultured wi th different concentrations of BR fractions in 
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F^. 4.20 Effect of BR fractions on the Fc receptor expression on mur ine 
resident peritoneal exudate cells 
EAq (0.1 ml, 10® cells/ml) and 0.1 ml of macrophages (1 x 10® cells/ml) from 
different groups of mice after treatment with PBS, BRIaii or BRIbii were 
mixed in centrifuge tubes, and then centrifuged at 100 xg for 10 minutes at 
4 � C . The cell pellet was incubated for 30 minutes at 4 � C . After incubation, 
the supernatant was flicked off and the cell pellet was resuspended in 
complete RPMI. The cell suspension was smeared onto glass slides, dried in 
air, fixed in methanol and stained with May Grimwald/Giemsa. Macrophages 
with three or more adherent erythrocytes were termed rosettes. The results 
were expressed as % of resetted cells. The differences between groups of 
control and treatment were determined by Student's t-teat. *P< 0.001; **P< 
0.005. Vertical bars represent one standard error. 
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mitogenic assay. Both BRIaii and BRIbii can partly restore the 
depressed mitogenic response observed in aged mice (Fig. 4.21). 
4.1.2.2 Effect of BR fractions on lymphocvte blastogenesis in tumour-
bearing mice 
Murine splenocytes from EAT^bearing mice were co-cultured wi th 
different concentrations of BR fractions in mitogenic assay. Both 
BRIaii and BRIbii could significantly restore the depressed 
mitogenic response in tumour-bearing mice (Fig. 4.22). 
4.2 DISCUSSION 
In vitro mitogenic assay was used to secreen die imimiROsiiimiiaiing aciivities 
of each BR fraction in the preliminary step, as it is one of the fast and 
economic ways in assaying the immune system. The crude extract of BR 
exhibited a very potent mitogenic activity on murine splenocytes. However, 
the so called crude extract may be impure. The crude extract was 
fractionated by stepwise alcohol precipitation to give five fractions (zero to 
four). Of these five fractions, BRzero carried the highest mitogenic activity 
in vitro, however, in the in vivo studies, its mitogenic activity was lower than 
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Fq. 4.21 Effect of BR fractions on lymphocyte blastogenesis i n aged 
mice 
Mur ine splenocytes (5 x 10^ cells/well) from either aged 
BALB/c mice or normal mice were co-cultured w i t h different 
concentrations of BR fractions. After an incubation period of 
48 hrs., cul tured cells were given a 6-hr. pulse w i t h 0.5 
fiCi/well ^H-TdR and radioactivi ty incorporated was 
determined. Vert ical bars represent two standard errors. 
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Rg. 4.22 Effect of BR fractions on lymphocyte blastogenesis i n tumour-
bearing mice 
Mur ine splenocytes (5 x 10^ cells/well) from EAT-bear ing mice 
were co-cultured w i t h di f ferent concentrations of BR fractions. 
Af ter an incubat ion period of 48 hrs., cul tured cells were 
given a 6-hr. pulse w i t h 0.5 f iCi/well ^H-TdR and rad ioact iv i ty 
incorporated was determined. Vert ical bars represent two 
standard errors. 
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that of BRI, which showed potent mitogenic activities on murine 
splenocytes. Moreover, BRzero was shown to contain LPS contamination 
using acetic acid. As a result, BRI was used for further studies. 
The mitogenic activities of either BRIa or BRIb were lower than that of 
BRI, i t may be due to slight contamination of BRI w i th LPS, also both 
fractions (BRIa and BRIb), as contained in BRI before purification, may act 
synergistically on murine splenocytes. 
After successive purification by gel f i l tration and anion exchange 
chromatography, four fractions (BRIai, BRlaii, BRIbi and BRlbi i) were 
produced. Of these four fractions, BRlbi i exhibited the most potent 
mitogenic activity followed by BRlaii. 
Before purification by anion exchange chromatography using DEAE 
sephadex, BRIa and BRIb were assayed for LPS contamination by co-
culturing w i th polymyxin B sulphate, which is nowadays used as a drug to 
cure bacterial infection. Fortunately, the results showed that no LPS 
contamination at this stage. As a result, further fractionation of BRIa and 
BRIb into BRIai, BRlaii, BRIbi and BRlbii should contain no LPS. 
Since splenocytes include both B cells and T cells, in order to prove 
whether the BR fractions isolated was a B-cell mitogen or T-cell mitogen, 
splenocytes were absorbed by antibodies to deplete either T cells or B cells. 
I 
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I t was found that BR fractions were B-cell mitogens. This finding agreed 
wi th results obtained from other Chinese herbs like Pseudostellaria 
beterophyllay Astragalus membranaceus, etc. However, BR fractions showed 
some T'cel l mitogenic activity, although their mitogenic activities on T cells 
were much lower than that on B cells. The hemolytic plaque assay was 
another evidence to show that BR fractions were 丁-cell mitogen, as the 
antigen used in this assay was SRBC, a T-cell dependent antigen. That 
I j 
means the humoral immune response cannot function well without the help 
of T cells. 
Besides the induction ofTj^ cell activity, BR fractions, especially BRIbi i were 
also found to be able to induce CTL activity. This is a very important 
immune response, as CTL play a primary role in defending the body against 
virus attack or tumour growth. 
In order to explore some other aspects of the immune system that BR 
fractions can stimulate, three cytokines were chosen to be studied for their 
production under the influence of BR fractions. Cytokines act as very 
important mediators between the immune cell types, their contributions to 
the immune system resembles the contributions of hormones to the 
endocrine system, or the neurotransmitters to the nervous system. The three 
cytokines we chose are three important cytokines. Two of them I L - l and IL-
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2 are responsible for coordinating the immune system. The third cytokine 
is GM'CSF, which is an important growth factors for myeloid cells. IL-Z can 
be used as an autocrine, that means IL '2 produced by a cell (mainly T cells) 
can be used by itself for farther activation. BRIbii was found to be a good 
inducer on the production of these three cytokines. These findings have 
direct correlation wi th the results of the previous assays, such as mitogenic 
assay, CTL assay and hemolytic plaque assay. I t is because BRIbii can induce 
the production of these cytokines, which in turn activate various cell types 
of the immune system. 
Apart from studying these cytokines, the receptor on lymphocyte for one of 
these cytokines was also delermined. Although the immunostimulating 
activities may be due to an increase in IL-Z production, however i t could be 
due to increase in IL'2R expression which in turn could enhance the 
utilization of IL'2. In our studies, BRIbii were found to be capable of 
enhancing IL-ZR expression on murine lymphocytes. The increase in IL^ZR 
expression could enhance the binding of IL-2, thus rendering the cells 
become more activated. 
Macrophages are multi-functional in the immune system. BRIbii was found 
to enhance in vivo migration of macrophages to the injection site. Also, 
increase in Fc receptor expression on the macrophages was found to be 
> 
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induced by BRIbii. W i t h the presence of Fc receptors, macrophages are 
capable of engulfing foreign cells via ADCC. In view of the importance of 
macrophages in the immune system, BRIbii, which can induce the activities 
of macrophages, could be a very good iminunopotentiator. 
On the other hand, BR fractions, especially BRIbii could restore the 
depressed immune response in aged mice or tumour-bearing mice by 
restoring lymphocyte proliferation activities. In this respect, BRIbii may be 
a potential immunopotentiators in treating the immunosuppressive status in 
various kinds of disease such as cancer, immunodeficiency, AIDS, etc. 
In conclusion, BRIbii, the acidic fraction purified from BRIb, exhibited the 
most outstanding immunomodulating activities. Our findings are consistent 
wi th the previous findings that polysaccharides extracted from Bupleuri radix 
could enhance spleen weight, peritoneal macrophage phagocytosis, specific 
anti'influenza virus antibody titers and lymphocyte transformation (Zhang 
and Chen, 1989). 
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5.1 RESULTS 
5.1.1 Cytostatic effect of BR fractions on murine tumour cell lines in vitro 
Tumour cell (5 x ICP) lines at their logarithmic phase of growth 
were co-cultured with various concentrations (62.5 - 500 jig/ml) of 
BRIaii or BRIbii in 0.2 ml 10% FCS in each well of a 96-well 
microtiter plate. After 48 hours of incubation at Y f C, the cells 
were pulsed with 0.5 j iCi ^H-TdR per well and the radioactivity 
incorporated was determined. Fig. 5.1 to Fig. 5.6 show the cytostatic 
effect of BRIaii and BRIbii on the growth of six murine cell lines. 
The percentages of suppression on these cell lines were found to be 
below 20, with the exception of PU5-1.8 cells, the percentage of 
suppression that BRIbii exerted on this cell type conld resrK 40 or 
more. 
5.1.2 Effect of BR fractions on the growth of tumour cells in vivo 
BALB/c mice in groups of five were injected i.p. wi th BRI (100 
jug/ml per mouse per day) or an equal volume of PBS for five 
consecutive days began on two days before tumour inoculation. EAT 
cells (1 X 10” were injected i.p. per mouse on day 0. The mice were 
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F均.5 . 1 Cytostatic effect of BR fractions on the growth of mur ine 
carcinoma 
EAT cells (5 x 10 ” at their logari thmic phase of growth were 
co-cultured w i t h various concentrations (62.5 - 500 呢 /m l ) of 
BR fractions i n 0.2 m l 10% FCS in each wel l of a 96-well 
microt i ter plate. Af ter 48 hrs. of incubation at 37®C, the cells 
were pulsed w i t h 0.5 ^C i ^H-TdR per wel l and the 
radioact iv i ty incorporated was determined. Results were 
expressed as % suppression w i t h reference to the control. 
Vert ical bars represent two standard errors. 
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Ftg. 5.2 Cytostatic effect of BR fractions on the growth of mur ine 
fibrosacroma 
L929 cells (5 x 10^) at their logarithmic phase of growth were 
co-cultured w i t h various concentrations (62.5 - 500 ^ig/ml) of 
BR fractions i n 0.2 m l 10% FCS in each well of a 96-well 
microtiter plate. Af ter 48 hrs. of incubation at 37®C, the cells 
were pulsed w i t h 0.5 ^Ci ^H-TdR per wel l and the 
radioactivity incorporated was determined. Results were 
expressed as % suppression w i t h reference to the control. 
Vertical bars represent two standard errors. 
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F^g. 5.3 Cytostatic effect of BR fractions on the growth of mur ine 
myeloid tumours 
M l cells (5 X 10 ” at their logarithmic phase of growth were 
co-cultured w i t h various concentrations (62.5 - 500 iig/ml) of 
BR fractions i n 0.2 m l 10% FCS in each well of a 96-well 
microtiter plate. Af ter 48 hrs. of incubation at 37^C, the cells 
were pulsed w i t h 0.5 \iCi ^H-TdR per wel l and the 
radioactivity incorporated was determined. Results were 
expressed as % suppression w i th reference to the control. 
Vert ical bars represent two standard errors. 
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F^. 5.4 Cytostatic effect of BR fractions on the growth of mur ine 
lymphoma 
MBL-2 cells (5 x 10^) at their logarithmic phase of growth 
were co-cultured w i t h various concentrations (62.5 - 500 
jig/ml) of BR fractions in 0.2 m l 10% FCS in each wel l of a 96-
well microtiter plate. After 48 hrs. of incubation at 37®C, the 
cells were pulsed w i t h 0.5 j iCi ^H-TdR per wel l and the 
radioactivity incorporated was determined. Results were 
expressed as % suppression w i th reference to the control. 
Vert ical bars represent two standard errors. 
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Fig. 5.5 Cytostatic effect of BR fractions on the growth of mur ine 
fibrosacroma 
WEHI-164 cells (5 x 10^) at their logarithmic phase of growth 
were co-cultured w i th various concentrations (62.5 一 500 
lig/ml) of BR fractions in 0.2 m l 10% FCS in each wel l of a 96-
well microtiter plate. After 48 hrs. of incubation at 37^C, the 
cells were pulsed w i th 0.5 p,Ci ^H-TdR per wel l and the 
radioactivity incorporated was determined. Results were 
expressed as % suppression w i t h reference to the control. 
Vertical bars represent two standard errors. 
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Fig. 5.6 Cytostatic effect of BR fractions on the growth of murine 
macrophage-like tumour 
PUS-1.8 cells (5 X 10 ” at their logarithmic phase of growth 
were co-cultured w i t h various concentrations (62.5 - 500 
^ig/ml) of BR fractions in 0.2 m l 10% FCS in each wel l of a 96-
well microtiter plate. After 48 hrs. of incubation at 37^C, the 
cells were pulsed w i th 0.5 j iCi ^H-TdR per well and the 
radioactivity incorporated was determined. Results were 
expressed as % suppression wi th reference to the control. 
Vertical bars represent two standard errors. 
Ch. Five The Anti-tumour Activities 140 
sacrificed, and tumour cell number was counted. The mean EAT cell 
numbers in the groups of BRI, BRIa, BRIb, BRIaii and BRIbii were 
relatively lower than that of the control (Fig. 5.7 ‘ Fig. 5.9). For 
those groups treated wi th BR fractions, the percentage of suppression 
on growth of EAT cell in vivo was 40 or so. The differences between 
groups of the control and treatments were statistically significant 
(P<0.0001). 
For the growth of MBL'2 cells in C57BL/6J mice, the percentage of 
suppression that BRIaii exerted on the cells was 41. In comparison 
wi th the control, the difference was statistically significant 
(P<0.005) (Fig. 5.10). 
For the growth of WEHI-164 cells in BALB/c mice, the percentage 
of suppression that BRIaii exerted on the cells was 65. However, the 
difference between groups of control and treatment was not 
significant (P= 0.0914), because these groups had significantly 
different SDs (Table 5.1). 
5.1.3 Effect of BR fractions on the survival of EAT^bearing mice 
BALB/c mice in groups of twenty were injected i.p. with BRI (100 
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F^. 5.7 Effect of BR fractions on the growth of EAT cells in vivo 
BALB/c mice in groups of five were injected i.p. w i t h BRI (100 
^ig/ml) or an equal volume of PBS for five consecutive days 
began on two days before tumour inoculation. EAT cells (1 x 
10®) were injected i.p. per mouse on day 0. Tumour cell no. 
was determined on day 7. The differences between groups of 
control and treatment were determined by Student's t-test. *P< 
0.0001. Vert ical bars represent one standard error. 
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PBS BRIa BRIb 
F^. 5.8 Effect of BR fractions on the growth of EAT cells in vivo 
BALB/c mice i n groups of five were injected i.p. w i t h BRIa or 
BRIb (100 ^ig/ml) or an equal volume of PBS for five 
consecutive days began on two days before tumour 
inoculation. EAT cells (1 x 10®) were injected i.p. per mouse 
on day 0. Tumour cell no. was determined on day 7. The 
differences between groups of control and treatment were 
determined by Student's t-test *P< 0.0001. Vert ical bars 
represent one standard error. 
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F?g. 5.9 Effect of BR fractions on the growth of EAT cells in vivo 
BALB/c mice in groups of f ive were injected i.p. w i t h BRIa i i 
or BRIbi i (100 |ig/ml) or an equal volume of PBS for five 
consecutive days began on two days before tumour 
inoculation. EAT cells (1 x 10®) were injected i.p. per mouse 
on day 0. Tumour cell no. was determined on day 7. The 
differences between groups of control and treatment were 
determined by Student's Uest. *P< 0.0001. Vert ical bars 
represent one standard error. 
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Fig. 5.10 Effect of BR fractions on the growth of MBL-2 cells in vivo 
C57BL/6J mice i n groups of five were injected i.p. w i th BRla i i 
or BRlb i i (100 ^ig/ml) or an equal volume of PBS for five 
consecutive days began on two days before tumour 
inoculation. MBL-2 cells (2 x 10^) were injected i.p. per mouse 
on day 0. Tumour cell no. was determined on day 7. The 
differences between groups of control and treatment were 
determined by Student's t-test, *P< 0.005; **P< 0.1. Vertical 
bars represent one standard error. 
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Table 5.1 In vivo anti-tumour assay on WEHI-164 cells 
PBS 2.47 土 0.86 
BRIaii 0.802 ± 0.13 
BRIbii 2.132 ± 0.27 J 
BALB/c mice in groups of five were either treated with 0.2 ml BR 
fractions in PBS (500 pg/ml) or an equal volume of PBS injection 
i.p, per mouse on day 0, 1, 2, 3 and 4. On day 2 afternoon, WEHI-
164 cells (1 X 10” were injected s.c. per mouse. On day 9, the 
mice were sacrificed, and tumour weights were determined. The 
results were expressed as mean ± S.E•M./g/mouse• The differences 
between groups of control and treatments were determined by 
Student,s t-test, and the differences found were not significant 
(P=0.0914). 
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ixg/ml) or an equal volume of PBS for five consecutive days began 
on two days before tumour inoculation. EAT cells (1 x 10^) were 
injected i.p. per mouse on day 0. The mean survival time of BR' 
treated and the control groups were 20.4 days and 17.85 days 
respectively (Fig. 5.11). The difference between groups was very 
significant (P< O.OOOl). 
5.1.4 Ex vivo induction of natural killer cell activity by BR fractions 
D2754abelled Y A C 4 cells (1 x 10^) were cultured with splenocytes 
(1 X 10” from BALB/c mice of different groups of treatment at 37®C 
for 4 hours. The cells were then labelled with another fluorescent PI 
(5 fig/ml). Death of target cells was assessed by fluorescence 
microscopy with a 495 nm filter. The percentages of cytotoxicity on 
target cells for the groups of treatment with BRIaii and BRIbii were 
77.08 and 59.07 respectively. The difference between groups of the 
control and treatment with BRIaii was statistically significant 
(P<0.005). 
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F^. 5.11 Effect of BR fractions on the survival of EAT-bearing mice 
BALB/c mice i n groups of twenty were injected i.p. w i th BRI 
(100 ^ig/ml) or an equal volume of PBS for f ive consecutive 
days began on two days before tumour inoculation. EAT cells 
(1 X 10®) were injected i.p. per mouse on day 0. The mean 
survival t ime of BR treated and the control groups were 20.4 
士 0.4 and 17.85 土 0.3 days respectively, and the difference 
determined by Student's ^-test was very significant. (P< 
0.0001). 
！‘ , 
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F^. 5.12 Effect of BR fractions on the induction of N K cell act iv i ty 
D275-labelled YAC-1 cells (1 x 10^) were cultured w i t h 1 x 10^ 
splenocytes from BALB/c mice of different groups of treatment 
at 37^C for 4 hrs. The cells were then labelled w i t h another 
fluorescent P I (5 ^ig/ml). Death of target cell was determined 
by fluorescence microscopy w i t h a 495 run filter. The results 
were expressed as the % of cytotoxicity w i th reference to the 
control group. The differences between groups were 
determined by Student's t-test, *P< 0.005. Vert ical bars 
represent one standard error. 
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5.1.5 In vitro induction of LAK cell activity by BR fractions 
BALB/c mouse splenocytes (5 x 10^) were co-incubated wi th BR 
fractions (200 ^g/ml) and/or rIL^2 (50 U/ml) for 3 days at 37。C. 
Viable effector cells (1 x 10” were added to 4 x 10^ W E H M 6 4 
target cells and incubated for 24'hr. at 37^ C. The cell mixture were 
washed and the cells remained were stained with neutral red and 
lysed by SDS. The absorbance at 540 nm was read. The percentages 
of cytotoxicity on target cells for the groups of BRIaii and BRIbii 
were 64 and 70 respectively (Fig. 5.13). IL'2 was found to have 
synergistic effect wi th these BR fractions. For the groups of BRIaii 
and BRIbii that co-incubated wi th IL-2, the percentages of 
cytotoxicity on target cells were 75 and 72 respectively. The 
differences between groups of the control and treatments were 
statistically significant. 
5.1.6 In vivo induction of T IL by BR fractions 
BALB/c mice in groups of five were injected s.c. with 1 x 10^ 
WEHM64 cells in 0.2 ml PBS on day 0. Starting from day 18, the 
mice were injected i.p. wi th either 0.2 ml BRIaii (10 mg/ml) or an 
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F^. 5.13 Effect of BR fractions on the induction of L A K cell act iv i ty 
BALB/c mouse splenocytes (5 x 10®) were co-incubated w i th 
BR fractions (200 ^ig/ml) and/or r IL-2 (50 U/ml) for 3 days at 
37^C. Viable effector cells (1 x 10®) were added to 4 x 10^ 
WEHI-164 target cells and incubated for 24 hrs. at 37®C. The 
cell mixture were washed and the cells remained were stained 
w i th neutral red and lysed by SDS. O.D.540 was determined. 
The results were expressed as % cytotoxicity on WEHI-164 
cells. The differences between groups of treatment were 
determined by Stiident»s f-test. *P< 0.05; **P< 0.005; ***P< 
0.0005. Vert ical bars represent one standard error. 
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equal volume of PBS for 3 consecutive days. On day 23, the mice 
were sacrificed, the tumour mass was removed , weighed and 
disaggregated. TIL were obtained by gradient centrifagation. The cell 
suspension was counted. T IL was depleted by incubating with and-
Thy 1.2 Ab and complement. The remaining cell suspension was 
counted again. T IL number could be determined by subtracting the 
second cell no. from the first one. For the group of mice treated 
with BRIaii, the TIL number per unit weight of tumour was 2.72 x 
10〜which was statistically significant (P<0.005) when compared to 
control i l .34 x 10^) (Table 5,2). 
5.1.7 In vitro induction of niacrophage-tnediated cytostatic effect on 
tumour cells by BR fractions 
Resident macrophages from normal BALB/c mice were obtained 
from peritoneal cavity. 50 of macrophage suspension (1 x 10 
cells/ml), 100 ^il of L929 cells (5 x 10^ cells/ml) and 50 of BR 
fractions (62.5 - 250 ^g/ml) were co-incubated in each well of a 24' 
well plate at 37° C for 48 hours. The cell mixtures were pulsed with 
0.5 ^iCi ^H-TdR per well for an additional 6'hour incubation. The 
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Table 5.2 Effect of BRIaii on tumour-infiltrating lymphocytes 
(TIL) number enhancement 
：：：：：：>：：：：；：；：；：；：；：；：；：；：；：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：：>：：；：；：；：；：；：；：；：^ ：：：：：;：：：：：;：;：：：：：：：：：：：>：：：：：：；：：>：：：：：：：：：：；：•：；：；：；：；：；：：：;：：：：：：：：：：：：：：：：：：：：：：：：> 
= S = = 
PBS 2.05 X 108 1.34 X 108 ± 3.6 X 106 
BRIaii (*) 3.50 x 10^ | 2.72 x 10^ ± 6.5 x 10^ 
5 
BALB/c m i c e fn-項roups ©S^five were injected s.c. with 1 二 10 
WEHI-164 cells in 0.2 ml PBS on day 0. Starting from day 18, the 
mice were injected i.p. with either 0.2 ml BRIaii (10 mg/ml) or 
an equal volume of PBS for 3 consecutive days. On day 23, the 
mice were sacrificed, the tumour mass was removed, weighed and 
disaggregated. TIL were obtained by gradient centrifugation. The 
cell suspensions was counted. TIL was depleted by incubating with 
anti-Thy 1.2 Ab. and complement. The remaining cell suspension 
was counted again. TIL number could be determined by subtracting 
the second cell number from the first one. The results were 
expressed as the TIL number per unit weight of solid tumour (mean 
± S.E.M.). The treatment group was compared with the control 
group, and the differences were determined by Student's t-test. 
* P<0.005, 
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radioactivity incorporated was determined. The percentage of 
suppression for group treated wi th BRIaii or BRIbii was around 16. 
In comparison wi th the control group, the differences were 
significant (BRIaii： P<0.005 • P<0.05； BRIbii： P<0.0001 - P< 
0.01)(Fig. 5.14). 
5.1.8 In vitro induction of macrophage-mediated cytolytic effect on tumour 
cells by BR fractions 
BALB/c mice PEC (2 x 10^), ^H^TdR^abelled L929 cells and 
different concentrations of BR fractions (0.5 and 1 mg/ml) were c o 
- , . 一 - 产 - 广 “ . ‘ > . • . 〜 - -
incubated in a final volume of 1.5 ml at 37 C for 48 hours. After 
incubation, the cell suspensions were centrifuged at 200 xg for 10 
minutes to sediment cell debris and the culture supernatant (0.2 ml) 
was transferred and added to 5 ml of scintillant. The radioactivity 
was determined. The net ^H-TdR release for the group of BRIaii 
(333 Jig/ml) was 19,304 cpm (PcO.OOOl); while for the group of 
BRIbii (333 ^ig/ml), the net ^H-TdR release was 3618 cpm 
(P<a0005)(Fig. 5.15). 
Fig. 5.16 showed the results of the same assay on WEHI464 cells. 
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F^. 5.14 Effect of BR fractions on macrophage-mediated cytostasis on 
tumour cells 
Resident macrophages from normal BALB/c mice were 
obtained from peritoneal cavity. 50 m-I of macrophage 
suspension 
(1 X 10^ cells/ml), 100 ^il of L929 cells (5 x 10^ 
cells/ml) and 50 of BR fractions (62.5 -250 ^ig/ml) were co-
incubated in each wel l of a 24-well plate at 37。C for 48 
hours. The cell mixtures were pulsed w i t h 0.5 ^iCi ^H-TdR (in 
200 ^il RPMI) per wel l for an additional 6-hour incubation, 
prior to cell harvesting. The radioactivity incorporated was 
determined. Vert ical bars represent two standard errors. 
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f ig . 5.15 Effect of BR fractions on macrophage-mediated cytolysis on 
tumour cells 
BALB/c mouse PEC (2 x ^H-TdR-labelled L929 cells (2 x 
10^) and different concentrations of BR fractions (0.5 and 1 
mg/ml) were co-incubated in a f ina l volume of 1.5 m l at 37 C 
for 48 hours. After incubation, the cell suspensions were 
centrifuged at 200 xg for 10 minutes to sediment any debris 
and 0.2 m l of the culture supernatant was transferred and 
added to 5 m l of scint i l lant. The radioactivity release was 
determined. The differences between groups of treatment and 
control were determined by Student's ^-test. *P< 0.0005; **P< 
0.0001. Vert ical bars represent one standard error. 
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The net ^H-TdR releases for the group of BRIaii (166 and 333 
jig/ml) were 52,100 and 51,286 cpm respectively (P<0.05), while the 
net ^H'TdR releases for the group of BRIbii (166 and 333 )ig/ml) 
were 49400 and 46523 cpm. respectively and differences between 
groups of the control and treatments with BRIbii were not 
significant. 
5.1.9 Effect of BR fractions on ^-interferon production in vitro 
Both BRIaii and BRIbii were able to induce cultured splenocytes to 
pnxbce公IFN'Y. A .jpurine IFN-y ELISA kit was employed to 
determine the IFN-y released by these splenocytes. I t was found that 
both BRIaii and BRIbii could significantly induce IFN-y production 
to 2700 and 2200 pg/ml supernatant respectively at the 
concentration of 500 (ig/ml of BR fractions. 
52 DISCUSSION 
The in vitro cytostatic effects of BR fractions on murine tumour cell lines 
were relatively weak, wi th the exception of PU5'1.8 cell lines. As PU54.8 
is a macrophage'transforming cell line, it possesses the ability of 
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Fig. 5.16 Effect of BR fractions on macrophage-mediated cytolysis on 
tumour cells 
BALB/c mouse PEC (2 x 10”，^H-TdE-labelled WEHI-164 cells 
(2 X l O ” and different concentrations of BR fractions (0.5 and 
1 mg/ml) were co-incubated i n a f inal volume of 1.5 m l at 37 
C for 48 hours. After incubation, the cell suspensions were 
centrifuged at 200 xg for 10 minutes to sediment any debris 
and 0.2 m l of the culture supernatant was transferred and 
added to 5 m l of scint i l lant. The radioactivity release was 
determined. The differences between groups of treatment and 
control were determined by Student^s ^-test. *P< 0.05. Vertical 
bars represent one standard error. 
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Fl^. 5.17 Effect of BR fractions on y-interferon production 
Splenocytes (5 x 10勺 f rom BALB/c mice were cultured w i th 
0.2 m l 10% FCS or BR fractions in 10% FCS (62.5 - 500 ^ig/ml) 
at 37^C for 2 days i n a 5% CO^ incubator. Supernatants were 
collected by spinning down the cells at 400 xg for 5 minutes, 
and IFN-y were determined by IFN-y ELISA k i t . 
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phagocytosis. The relatively strong cytostatic effects of BR fractions on PU5' 
1.8 may be due to the assumption that PUS-l.S cells ingested the 
macromolecules of BR, causing internalization which in turn gave rise to the 
intracellular cytotoxic effect on PU54.8 cells themselves. 
Despite the above exception on PU5-1.8 cells, the cytostatic effects of BR 
fractions on most tumour cell lines can be considered a weak action. That 
means the anti-tumour effects of BR fractions should not be a direct 
cytotoxic effect, but may be a series of actions that mediated through some 
other indirect mechanisms. 
On the other hand, the anti-tumour effects of BR fractions was supported 
by the findings that the growth of tumour cells in tumour-bearing mice was 
suppressed to a certain degree (〜40%). BRIaii was found to be a more 
powerful anti-tumour agent, in terms of suppression of tumour cell number 
and prolongation of survival time. 
The difference in findings between the in vitro and in vivo studies indicates 
that BR fractions (especially BRIaii) are able to induce anti-tumour activities 
through some host-mediated mechanisms. This finding is consistent to the 
findings that the BR fractions could stimulate macrophages or lymphocytes 
to increase in cytotoxicity or release of cytokines against tumour cells. 
BR fractions can induce a number of cell-mediated cytotoxicity. I t was found 
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that NK cell activity can be induced by BRIaii. The anti-tumour effect of 
LAK cells was believed to be better than NK cells. Our results showed that 
both BRIaii and BRIbii can induce LAK cell activity. The inducing ability 
of BR fractions was similar to that of IL'2’ and showed synergistic activity 
with IL '2 on LAK cell cytotoxicity. 
I t was reported that T IL is another potent cell type that can mediate 
cytotoxicity on tumour cells. The cytotoxic ability of T IL can be enhanced 
by culturing with rIL'2 in vitro. Also, T IL cultured in vitro can be transfected 
by an activated TNF gene, so TIL, once reinjected into the tumour site, may 
release intratumour TNF, which is a more effective way in kil l ing tumour 
cells whatever the sensitivity of the tumour to TNF (Rosenberg, et oL, 
1990). In our studies, T IL was isolated from a fibrosarcoma (WEHI'164) 
grown in vivo. I t was found that the number of TIL isolated from the group 
of mice treated with BRIaii was increased, as compared to control. However, 
owing to the inadequate technique of gradient centrifiigation, the T IL 
isolated was not pure enough to be used for further culture wi th rIL'2. Our 
preparation contained 60% or less T IL (data riot shown) and large 
proportion of tumour cells, rendering further culture of T IL impossible, as 
80% or more TIL is needed for further culture (Cao, et al., 1989). 
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Although the cytotoxicity assay of the T IL could not be obtained. However, 
it is certain that BRlaii can enhance TIL number. Nevertheless the 
mechanism by which TIL increase in number is stil l unknown. I t may be 
due to the increase in migration of T cells to the tumour sites or increase in 
proliferation of the lymphocytes infiltrated in tumours or both. 
The majority of TIL at the init ial stage of culturing with IL'2 was CTL, but 
25 days later, the majority of T IL became Tj^ cells (Cao, et d ” 1989). This 
implies that the anti'tumour activities of cultured T IL were the strongest for 
the first 25 days in cell culture. 
Since the antitumour effect of T IL is 50 - 100 fold better than LAK cells 
‘ ； : , . . . . . . 
(Cao, et d； 1989), it is more appropriate. to be used in adoptive 
immunotherapy (AIT) than LAK cells. I t is because (1) TIL is specific to 
target cells, especially those tumour cells which are resistant to treatment 
with LAK cells; (2) TIL requires trace amount of IL '2 to perform its anti ' 
tumour effect in ATT, therefore side effects to the host of using IL'2 can be 
reduced; (3) When cultured wi th IL'2, the proliferation rate of T IL is higher 
than that of LAK cells, so T IL can easily fulf i l the required cell number in 
A I T (Cao, et d； 1990); (4) The anti-tumour effect of T IL is partly due to 
the ability to release TNF, which, apart from, direct kill ing of tumour cells, 
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can induce further attraction and activation of attracted cells to participate 
in cell-mediated cytotoxicity (Vassalli, 1992). 
Macrophages are another cell type that can mediate cytotoxicity on tumour 
cells. Two macrophage-mediated effects on tumour cells were studied. 
Macrophages were found capable of exerting cytostatic effect and cytolytic 
effect on tumour cell lines. Both BRIaii and BRIbii can induce macrophage-
mediated cytolysis on L929 cells, but only BRIaii can induce macrophage-
mediated cytolysis on WEHI'164 cells and macrophage'tnediated cytostasis 
on L929 cells. For the reasons that the inhibit ion of the growth of tumour 
cells in the,p^sence of rn^rophages may be due to the ROI (e.g. O,' or 
H jO j ) released by the macrophages. When macrophages are fully activated, 
certain cytolytic serine proteinase or TNF^a wi l l be released to destroy the 
tumour cells. Recent findings indicated that tumour-associated macrophages 
( T A M ) play a very important role in the formation of intratumoral fibrin, 
which can inhibit tumour cell invasion (Adany, 1993). 
Apart from assaying the cell-mediated cytotoxicity on tumour cells, the 
production of IFN-y induced by BR fractions was determined. EFN", an 
important cytokine released by T cells or NK cells, can prime macrophages 
for nonspecific tumoricidal activity. IFN-y stimulates monocytes or 
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macrophages to synthesize TNF, and TNF in turn mediates the kil l ing of 
some types of tumour cells by IFN-y activated monocytes/macrophages. Both 
BRIaii and BRIbii were found capable of inducing IFN'y production. 
Of all the fractions of Bupleuri radix,^ BRIaii so far showed the most 
satisfactory results on anti-tumour activities. 
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GENERAL DISCUSSION 
BRIaii was found to be a potent anti'tumour agent, while BRIbii was found to be 
a potent immunostimulating agent. BRIaii and BRIbii probably exert their 
activities through two mechanisms. In other words, BRIaii demonstrates its effect 
on one mechanism that leads to anti'tumour activities, whereas BRIbii 
demonstrates its effect on another mechanism that leads to immunostimulating 
activities. 
I t is believed that the anti-tumour activities are closely related to the 
immunostimulating activities. Many reports indicated that the anti-tumour 
activities are a host'-mediated response, which probably involves the immune 
system (Rosenberg and Lotze, 1986; Herlyn and Koprowski, 1988). Our results 
indicate that while BRIaii is not only a potent anti-tumour agent, it is also a 
strong immunostiinulating agent. The anti'tumour activities of BRIaii are host 
mediated. I t activates the macrophages or lymphocytes rendering them an increase 
of their tumouricidal activities. I t may also trigger the release of cytokines from, 
these cells and in turn activate the host cells. In order to understand more about 
the relationship of anti'tumour and immunostimulating activities, some parameters 
of the immune system were studied. 
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IL '2 is required to activate NK cells, LAK cells and T IL grown in vivo and these 
cells, w i th the exception of N K cells, are unable to perform cytotoxicity without 
IL'2. Recently, IL-Z was used clinically for treating cancer patients. However, there 
are a lot of side effects wi th IL '2 treatment (Cao, et a/., 1990). In our studies, 
BRIbii was found to induce IL '2 production in vitro. In this respect, i t may be 
speculated that BRIbii may replace IL-Z in both in vitro and in vivo use. I t is 
expected that the use of bioactive fractions from Bupleuri radix may minimize the 
side effects causing by IL'2. 
GM'CSF is anotherMytokine w l ^ h . is also known as：、growth factor' of myeloid 
cells. The clinical use of GM-CSF is to treat acute myeloid leukaemia (Buechner, 
et oL, 1989). BR fractions were found able to induce GM'CSF production. The 
increase in the level of GM^CSF can in turn induce the activation/maturation of 
macrophages, as well as the strengthening of neutrophils in kill ing the antibody-
coated tumour cells. IL-1 and TNF are also potent inducers of endothelial cell 
production of GM^CSF (Seelentag, et d； 1987). I n addition to GM-CSF, IFN-y 
is another cytokine that can activate macrophages. IFN-y is able to enhance Fc 
receptor expression for IgG on monocytes or macrophages, thus triggering the 
tumoricidal activity of these kinds of cells through ADCC. BR fractions can induce 
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the production of IFN^y. The inducing power of BRIaii on I F N " production is 
better than that of BRIbii. Here shows two more pieces of evidence that the anti-
tumour activities and the immunostiinulating activities are mutually dependent. 
So far many tumour-specific antigens (e.g. p21 RAS) were identified (Urban and 
Schreiber, 1992; Schreiber, et cd” 1988). Some of these tumour antigens can elicit 
the acquired immunity of the body. Although cell-mediated reactions are probably 
of greater significance in the defence against tumours, antibodies against tumour 
antigens which are detectable in sera can recruit cells carrying Fc receptors to 
perform ADCC Bl^fractiom j^||icli were found capable of enhancing both Fc 
receptor expression and B cell activities may favor the induction of ADCC on 
tumour cells. 
Some recent studies showed that T IL mount a multifaceted immunological attack 
against several independent tumour antigens. For example, TIL from a human 
ovarian adenocarcinoma can recognize at least three distinct tumour-associated 
antigens (loannides, et d., 1991). In view of this, it is encouraging to note that 
tumour cells can express multiple targets to be recognized by the immune system. 
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Normally, each member of the immune system cooperates with each other in 
order to achieve a certain function. For example, inflammation involves the 
actions of neutrophil, macrophages, complement and some cytokines. This 
principle is also true for the anti'tumour activities. Anti 'tumour activities are 
complex activities that require a series of actions mediated via the immune system. 
However, the detailed mechanism is still not fully explored. Immune system should 
be viewed as a whole and it is unwise to isolate certain immunological parameters 
from the whole system when examining the anti-tumour activities. 
The anti-tumour activities are p^ved to be one of the properties of the immune 
system, but the magnitude of these activities is usually very low. In order to 
upregulate these activities, certain natural products like Bupleuri radix may help to 
booster the immune system, so that the immune system becomes strong enough to 
defend the body against tumour cells. Generally speaking, the using of natural 
products in treating cancer may be beneficial to the host body, as they have litt le 
toxicity and side effects as evidenced by the brine shrimp bioassay. 
CONCLUSION 
BR fractions, extracted from the dry roots of Bupleuri radix, show 
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immunostimulating and anti-tumour activities. Of these fractions, BRIaii is the 
most potent fraction for anti-tumour activities, while BRIbii 至s the most potent 
fraction for immunostimulating activities. 
The imniunostimulating activities of BR fractions may partly explain the 
mechanism, of the anti-tumour activities. 
FUTURE PROSPECTS 
As all BR fractions contain a minor portion of protein, it is very interesting to 
examine whether there is any contribution of the protein moiety to both 
immunostimulating activities and anti-tumour activities. The protein content of 
the fraction can be digested by enzymes, and the final product wil l be taken to 
assay for the above activities. 
The types of the monosaccharide that compose the polysaccharides of each fraction 
can be determined by gas chromatography. Also, the tertiary structure of 
polysaccharides can be determined by X'ray crystallography or nuclear magnetic 
resonance. As a result, structure-function relationship can be obtained 
MTX is an anti-cancer drug used nowadays, but i t is rather toxic when high dose 
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of it is used. BR fractions can be assessed for whether there is synergistic effect 
wi th MTX. I f there is a synergistic effect, the dose of MTX can be reduced. 
Lastly, T IL can be further purified and cultured with rIL-2 in vitro, in order to 
assess the cytotoxicity of T IL on tumour cells. A t the same time, the variations of 
surface markers are studied, thus the cell types of TIL can be identified. 
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